Red, White, and Platelets: A Detective Story in a Single Tube of Blood

At two in the morning, the hematology consult pager goes off. A 4-year-old boy has a high fever and bone pain so severe he refuses to walk; his labs show a white count of 35,000, platelets of 20,000, and hemoglobin of 6. In the next ward, a 62-year-old man has been admitted for three days with "low back pain, anemia, and rising creatinine" — the on-call physician freezes at the bedside, staring at an electrophoresis report with an implausibly tall monoclonal spike. Down in the emergency department, a 28-year-old postpartum woman has suddenly erupted in large bruises across her body; her aPTT is prolonged while her PT is entirely normal, and factor VIII sits at only 3% — yet the mixing test fails to correct.

On the surface, these three patients have nothing in common. But if you speak the language of hematology, you will see they are all telling the same story — some pathway of hematopoiesis or hemostasis has been interrupted, and it is the manner of interruption that carves out entirely different diseases. The hematology-oncology section of the licensing exam is hard precisely because it never merely asks you to memorize a diagnosis; it asks you to reason like a detective — to look at an MCV, a fusion gene, a platelet count, a mixing-test result, and deduce exactly which cell, at which stage, was broken by what.

This issue begins at the very source — the hematopoietic stem cell (HSC) — and follows the thread through red-cell maturation, the two-axis triage of anemia, the four quadrants of leukemia, the monoclonal proliferations of lymphoma and myeloma, and the PT/aPTT coordinate system of bleeding and clotting, all the way to pediatric solid tumors, oncologic emergencies, and transfusion medicine. By the end, you will find every test point strung on the same chain of reasoning: return to the cell first, and the disease answers itself.

1. The Hematopoietic Tree: One Family Chart Locates Every Cell

Every story in hematology begins at the same source — the hematopoietic stem cell (HSC) residing in the bone marrow. It first divides into two main trunks, the myeloid and lymphoid lineages, which then branch further into every number you see on a complete blood count. To make sense of any blood disorder, you must first hold this tree in your mind; once you have that coordinate system, "why does one cell type change together with another" no longer needs to be memorized by rote.

The Hematopoietic Tree: One Diagram, One Entire Textbook of Hematology

To memorize the hematopoietic tree, start with a single sentence: platelets and red cells "share a root" — they arise from a common precursor called the MEP (megakaryocyte-erythrocyte progenitor). This is why, in aplastic anemia, marrow infiltration by tumor, or chemotherapy-induced myelosuppression, you so often see hemoglobin and platelets fall together — never a coincidence.

Precursor	Progeny	One-line summary
HSC	Ancestor of every blood cell	Self-renewal + multilineage differentiation
CMP (common myeloid progenitor)	MEP + GMP	Gateway to the myeloid lineage
MEP	Megakaryocytes (→ platelets) + erythrocytes	Platelets and erythrocytes "share a root"
GMP (granulocyte-monocyte progenitor)	Granulocytes (neutrophils/eosinophils/basophils) + monocytes	Source of the granulocytes
CLP (common lymphoid progenitor)	T / B / NK lymphocytes	The sole origin of all lymphocytes

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

🔬 Mechanism, unpacked

Why is this tree the mother question of every hematology exam item? Break the causal chain into five steps: ① the HSC combines self-renewal with multilineage differentiation, so the marrow can both replenish blood and sustain itself indefinitely; ② the first fork splits into the myeloid CMP and the lymphoid CLP, and this single cut decides whether a malignancy is myeloid or lymphoid; ③ the CMP further divides into the MEP and the GMP, so the pair "platelets + red cells" rises and falls together, and the pair "granulocytes + monocytes" does likewise; ④ in aplasia or marrow crowding, the cells closest to the root fail first, so pancytopenia — all three lineages down — is common; ⑤ the lymphoid lineage branches off independently from the CLP, so lymphoid leukemia does not directly implicate platelet production unless the entire marrow has been crowded out of space. One tree explains every question about why blood cell counts change as a group.

The Erythroid Maturation Sequence: The Nucleus Tells You Whether a Cell Can Still Divide

Erythroid maturation, from bone marrow to peripheral blood, follows roughly this sequence: proerythroblast → basophilic erythroblast → polychromatic erythroblast → normoblast (orthochromatic erythroblast) → reticulocyte → mature erythrocyte. The exam's favorite question is never the name itself, but which stage can still divide and which stage still carries a nucleus.

Stage	Nucleus	Capable of division?
Proerythroblast through polychromatic erythroblast	Nucleated	Can divide
Normoblast	Still nucleated (condensed), about to extrude its nucleus	No longer capable of division
Reticulocyte	Anucleate (still contains RNA; visible as a reticular network on supravital stain)	Does not divide
Mature erythrocyte	Anucleate, 6–8 μm in diameter, lifespan ~120 days	Does not divide

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

The normoblast is "the last stage that still has a nucleus but no longer divides" — never equate having a nucleus with being able to divide.

Once you understand this sequence, the reticulocyte is no longer a strange term: it has just extruded its nucleus but still contains RNA, so a special stain reveals its reticular structure on smear; its abundance is the most direct indicator of the marrow "working overtime to restock" — a concept the next chapter uses directly to calculate the RPI. As for the mature erythrocyte, it is the most numerous cell in the blood, with a 120-day lifespan; if you ever see an answer choice claiming "the most numerous cell in the blood is the leukocyte," eliminate it immediately.

Primary vs. Secondary Lymphoid Organs: The Thymus Is the King of Traps

Lymphoid organs come in two kinds, and exam questions love to bury a trap inside the thymus.

	Primary	Secondary
Organs	Bone marrow, thymus	Lymph nodes, spleen, tonsils, Peyer's patches
Function	Lymphocyte generation and maturation	Antigen encounter; the site where the immune response occurs
Germinal centers	Absent	Present

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

The thymus is where T cells finally complete their education: the cortex is densely packed with T lymphocytes, and the medulla contains Hassall's corpuscles — yet it forms no lymphoid follicles and has no germinal centers, which is the reversed distractor the licensing exam loves most. Peyer's patches, in contrast, live in the submucosa of the ileum as members of the gut-associated lymphoid tissue (GALT); they are aggregates of lymphocytes tasked with sampling luminal antigens — they are not capillaries, not endocrine cells, and not neural tissue, and those options exist purely to catch anyone who is unsure.

Platelets and Mast Cells: No Nucleus Does Not Mean No Organelles

Platelets are small fragments shed from the cytoplasm of the megakaryocyte: after growing from an MEP all the way into a mature megakaryocyte, the entire cytoplasm fractures into thousands of pieces, each piece becoming one platelet. Platelets therefore have no nucleus — but that does not mean they have nothing at all. They still carry microfilaments (actin/myosin, responsible for the shape change and contraction that follow activation), alpha and dense granules (prepackaged by the megakaryocyte; the platelet itself has no typical Golgi apparatus), and mitochondria (supplying energy). The reversed trap the exam loves is "no nucleus, therefore no organelles" — entirely wrong. A platelet is an anucleate micro-factory, not an empty shell.

As for the mast cell — although its name is often paired with the basophil, and both release histamine, it does not circulate in normal blood at all. It resides mainly in tissue: beneath the skin, in connective tissue, and beneath the intestinal mucosa, waiting to be triggered by IgE. So "the cell least likely to be seen on a peripheral blood smear is the mast cell" is a gift question. The cell not to confuse it with is the basophil, which is in fact the least abundant leukocyte in blood (<1%) — but one that does circulate.

Marrow Sinusoids and Lymphatic Capillaries: Two Entirely Different Kinds of Vessel Wall

The last frequently tested histological detail hides inside the question of "how newly made blood cells enter the circulation." The sinusoids of the bone marrow have a relatively intact endothelial barrier — this question bank calls it a "closed circulation" — and newly formed blood cells must actively cross the endothelium (diapedesis) to enter the bloodstream. The megakaryocyte has an elegant shortcut instead: it extends long cytoplasmic processes directly into the sinusoidal lumen, where they are sheared into individual platelets and released.

The lymphatic capillary is the exact opposite: it begins as a blind-ended tube in the tissue, its endothelial cells joined by overlapping flaps, and its basement membrane is discontinuous or altogether absent — hence its enormous permeability, which allows proteins and cells to enter with ease (this is precisely the lymphatic system's job of recovering interstitial fluid and large molecules). One-way valves appear only in the larger lymphatic vessels; the capillaries themselves have none.

One point about the "nature of bone marrow" that is often misunderstood is worth adding here: yellow marrow is neither "damaged" nor "fibrotic" marrow — it is inactive marrow occupied by fat cells; when the body requires hematopoiesis (for example, in severe anemia), it can revert to red marrow and resume work. The essence of yellow marrow, then, is fat, not fibrosis.

⭐ Board-exam essentials

Hematopoietic Tree and Marrow Histology — Must-Know Checklist

The shared precursor of platelets and red cells = MEP; lymphocytes arise solely from the CLP.
By the time erythroid maturation reaches the normoblast, the cell is "the last stage with a nucleus, no longer dividing"; the reticulocyte is already anucleate but still contains RNA.
The most numerous cell in the blood = the erythrocyte (120-day lifespan).
Primary lymphoid organs (bone marrow, thymus) have no germinal centers; only secondary organs do. The thymus has Hassall's corpuscles but no germinal center.
Peyer's patches = aggregates of lymphocytes in the submucosa of the ileum (GALT).
Platelets are anucleate but organelle-containing (microfilaments, mitochondria, secretory granules); "no nucleus" ≠ "no organelles."
The cell least likely to be seen on peripheral blood = the mast cell (it lives in tissue); the basophil is the least abundant circulating leukocyte.
Lymphatic capillaries = blind-ended, overlapping-flap junctions, discontinuous basement membrane, with valves appearing only in larger lymphatic vessels.
Yellow marrow = inactive, fat-filled marrow (not fibrotic), able to revert to hematopoiesis when needed.
Traps: describing the thymus as having germinal centers; describing Peyer's patches as capillaries or neural tissue; describing yellow marrow as fibrotic; swapping the basophil and the mast cell.

♪ Sing-along text — English rendering of the Mandarin song lyrics

🎵 Chapter song　血液腫瘤・造血樹Spotify Apple Music

Alternate take (Version B): Spotify · Apple Music

Sung in Mandarin by Otter Whistle · album 《醫學國考・血液腫瘤》 · the text below is an English rendering of the lyrics

Every story in hematology begins at the same source: the hematopoietic stem cell in the bone marrow first splits into two main trunks, the myeloid and lymphoid lineages, which then branch out into every number you see on your blood count. To make sense of any blood disorder, you must first hold this tree in your mind — once you have that coordinate system, you no longer need to memorize by rote why one cell type changes together with another. The single most important sentence is this: platelets and red cells share a root, arising from a common precursor called the megakaryocyte-erythrocyte progenitor. That is why, in aplasia, marrow infiltration by tumor, or chemotherapy-induced myelosuppression, hemoglobin and platelets so often fall together — never a coincidence, but the same tree cut at the same branch.

Every blood cell grows from the same hematopoietic tree; platelets and red cells share one branch, so falling together is never chance.

Following the common myeloid progenitor downward, one branch leads to the megakaryocyte-erythrocyte progenitor, which grows into megakaryocytes that release platelets and into erythrocytes; the other branch leads to the granulocyte-monocyte progenitor, which grows into neutrophils, eosinophils, basophils, and monocytes — which is why myeloid leukemia commonly disturbs several of these lineages at once. Lymphocytes take a separate path, arising from the common lymphoid progenitor and growing into T cells, B cells, and natural killer cells; lymphoid leukemia therefore usually does not directly implicate platelet production, unless the marrow has been crowded out of room to make other blood cells. Behind every seemingly independent blood-count number lies a connecting family tree — understand that tree, and a lab report stops being mere numbers and starts telling a story.

Erythroid growth begins in the bone marrow with the proerythroblast, passes through the basophilic and polychromatic erythroblast stages, and reaches the normoblast — remember that at this stage the nucleus has already condensed into a single dark clump and is about to be extruded, but the cell can no longer divide. Having a nucleus, then, is not the same as being able to divide; the normoblast is the last stage that still has a nucleus but no longer divides. Fix this principle firmly, and you will never again equate "nucleated" with "capable of division." After extruding its nucleus, it becomes a reticulocyte — anucleate, yet still containing RNA, so special staining reveals a reticular network. This marker of a cell that has just lost its nucleus but is not yet fully mature is the most direct evidence of whether the marrow is working overtime to restock, and the next chapter puts it to direct use when calculating the reticulocyte production index. The mature erythrocyte finally measures 6 to 8 micrometers in diameter, lives roughly 120 days, and is the most numerous cell in the blood — if you ever see an answer choice claiming the most numerous cell in the blood is the leukocyte, eliminate it immediately.

Every blood cell grows from the same hematopoietic tree; platelets and red cells share one branch, so falling together is never chance.

Lymphoid organs come in two kinds, and exam questions love to bury the thymus inside a trap. The primary lymphoid organs are the bone marrow and the thymus, the sites where lymphocytes are generated and mature; a germinal center, by contrast, is a reaction product that appears only after antigen meets lymphocyte, so it is seen only in the secondary organs — lymph nodes, spleen, tonsils, and Peyer's patches. The thymus has its own distinctive Hassall's corpuscles and a cortex densely packed with T lymphocytes, but it simply has no germinal center; treating the thymus as a lymphoid organ with germinal centers is the single most common point lost in histology. Peyer's patches live in the submucosa of the ileum as members of the gut-associated lymphoid tissue, formed from aggregates of lymphocytes tasked with detecting luminal antigens — they are not capillaries, not endocrine cells, and not neural tissue, and each of those distractors is designed specifically to catch anyone unsure of the material.

A platelet is a small fragment shed from the cytoplasm of a megakaryocyte, so it has no nucleus — yet it still carries microfilaments built from actin and myosin, which allow it to change shape and contract once activated, along with secretory granules prepackaged by the megakaryocyte and mitochondria that supply energy. No nucleus does not mean no organelles; a platelet is an anucleate micro-factory, not an empty shell. Mast cells and basophils are easily mistaken for each other — remember that the mast cell lives mainly in tissue, beneath the skin, in connective tissue, beneath the intestinal mucosa, waiting to be triggered by immunoglobulin E; it does not circulate in normal blood at all, so it is the cell least likely to appear on a peripheral smear. The basophil, meanwhile, is the least abundant leukocyte in the blood, but it remains a cell that does circulate.

The sinusoids of the bone marrow have a relatively intact endothelial barrier, so newly formed blood cells must actively cross the endothelium to enter the bloodstream; only the megakaryocyte extends long cytoplasmic processes directly into the sinusoidal lumen, where they are sheared into individual platelets and released — its own private shortcut. The lymphatic capillary works the opposite way: beginning as a blind-ended tube in the tissue, its endothelial cells joined by overlapping flaps, its basement membrane discontinuous or even absent, so its permeability is high and proteins and cells can enter with ease — precisely the lymphatic system's job of recovering interstitial fluid and large molecules; one-way valves appear only in the larger lymphatic vessels, never in the capillaries themselves. Last comes yellow marrow: neither damaged marrow nor fibrotic marrow, it is inactive marrow occupied by fat cells, able to revert to red marrow and resume hematopoiesis whenever the body needs it — its essence is fat, not fibrosis. Hold the hematopoietic tree as this chapter's central axis, and every question — which cells share a root, which stage first gains a nucleus, which organ does or does not have a germinal center — can be reasoned through in turn.

Every blood cell grows from the same hematopoietic tree; platelets and red cells share one branch, so falling together is never chance.

🌙 On-call challenge — take this chapter's patient in English (OET Station 1) →

2. The Two-Axis Detective Work of Anemia: MCV and RPI Triage Everything

Anemia looks bewildering at first, but it really rests on only two axes: MCV tells you whether the red cell grew the way it should, and the reticulocyte count and RPI tell you whether the marrow is trying. Make these two cuts first, and most questions already have their cause pinned down.

The First Cut: MCV Sorts Small, Normal, and Large

MCV	Type	Representative etiology
↓ (<80)	Microcytic, hypochromic	Iron deficiency anemia (IDA), thalassemia, anemia of chronic disease (some cases), sideroblastic anemia
Normal (80–100)	Normocytic	Acute blood loss, hemolysis, anemia of chronic disease (usually this type), aplastic anemia
↑ (>100)	Macrocytic	Megaloblastic anemia (B12/folate deficiency); non-megaloblastic causes: alcohol, liver disease, hypothyroidism, myelodysplastic syndrome (MDS)

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

🔬 Mechanism, unpacked

Why does MCV triage so cleanly? Break the causal chain into five steps: ① the size of a red cell is decided by a race between "how large the cytoplasm grows" and "whether DNA replication keeps up"; ② when iron is deficient, hemoglobin cannot be made, so the cytoplasm neither grows large nor stains deeply, giving a microcytic, hypochromic cell; ③ B12 or folate deficiency stalls DNA synthesis, so nuclear division cannot keep pace with cytoplasmic growth, and the marrow progenitor grows into an oversized cell whose DNA has fallen behind — on the periphery, this is macrocytosis; ④ a normal size means the marrow itself is fine but the cells have been "taken away" — either lost through bleeding, destroyed, or the marrow itself has gone on strike; ⑤ so MCV alone lets you triage first, thinking in three directions: "the raw material for synthesis is missing," "the synthetic machinery is jammed," or "the finished product is being seized."

Both iron deficiency anemia (IDA) and anemia of chronic disease (ACD) can be microcytic; the key discriminator is ferritin: in IDA the body is genuinely iron-depleted, so ferritin↓, TIBC↑, transferrin saturation↓; in ACD, inflammation raises hepcidin, which locks iron inside macrophages so it cannot be released, giving a ferritin that is normal or ↑ and a TIBC that is ↓. Ferritin is the only marker that actually falls in IDA — the cleanest watershed between the two. One more causal link worth adding: why does TIBC rise in IDA? Because iron deficiency → low ferritin → the liver compensates by synthesizing more transferrin → the blood's total iron-binding capacity rises accordingly — the reflex of "the more iron you lack, the harder you try to scavenge it."

Thalassemia is also microcytic, but its nature is entirely different: a defect in α- or β-globin chain synthesis causes ineffective erythropoiesis plus hemolysis, so iron status is usually normal or even elevated (especially in the chronically transfused), rarely deficient — the concern instead is iron overload. How do you distinguish it from IDA? Use the Mentzer index = MCV/RBC: below 13 favors thalassemia, above 13 favors iron deficiency; the RBC count in thalassemia is often not low (a compensatory overproduction), and the RDW is usually normal (whereas IDA raises the RDW). Finally, hemoglobin electrophoresis settles it — β-thalassemia trait shows HbA2 >3.5%, whereas IDA shows a normal or low HbA2.

As for macrocytosis, megaloblastic anemia is most often caused by B12 or folate deficiency; a hypersegmented neutrophil (>5 lobes) on smear is the hallmark. To tell B12 deficiency from folate deficiency, look at the neurologic findings: only B12 deficiency causes subacute combined degeneration (of the dorsal columns and corticospinal tracts); folate deficiency does not. The clinical iron rule: when megaloblastic anemia is suspected, never give folate alone — folate alone can correct the anemia while masking the neurologic damage of B12 deficiency, which continues to worsen underneath.

The Second Cut: RPI Reveals Whether the Marrow Is Trying

Looking at the reticulocyte percentage alone is misleading, since it is diluted by the hematocrit; it must be corrected into the reticulocyte production index (RPI):

RPI = Reticulocyte% × (patient's Hct ÷ 45) ÷ maturation correction factor

The maturation correction factor rises with the severity of anemia: Hct 45 → 1.0, 35 → 1.5, 25 → 2.0, 15 → 2.5.

For example: a retic count of 9% with Hct 23% takes a maturation factor of 2.0, giving RPI = 9 × (23/45) ÷ 2.0 ≈ 2.3.

RPI	Interpretation	Meaning
> 2–3	Good marrow compensation	Hemolysis or blood loss — cells are being destroyed or lost, and the marrow is working to restock
< 2	Inadequate marrow production	Nutrient deficiency (B12/folate/iron), aplastic anemia, marrow infiltration

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

The raw reticulocyte percentage is "uncorrected"; the RPI is the marrow's honest answer — it accounts for the dilution created by faster release as anemia worsens.

Localizing Hemolysis: Intravascular vs. Extravascular

If the RPI is high and hemolysis is the call, the next step is to localize where the hemolysis is occurring.

	Intravascular hemolysis	Extravascular hemolysis (spleen)
Mechanism	Red cells rupture directly within the vessel	Splenic macrophages phagocytose abnormal red cells
Haptoglobin	Markedly ↓↓ (consumed binding free Hb)	Normal or mildly reduced
Blood/urine free Hb	Hemoglobinuria	Absent
LDH	↑↑	↑
Representative diseases	PNH (paroxysmal nocturnal hemoglobinuria), ABO-incompatible transfusion, acute G6PD deficiency crisis	Hereditary spherocytosis (HS), autoimmune hemolytic anemia (AIHA), thalassemia

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

🔬 Mechanism, unpacked

Why does haptoglobin collapse so dramatically in intravascular hemolysis? Break the causal chain into five steps: ① haptoglobin is a scavenger protein made by the liver to "capture free hemoglobin"; ② in intravascular hemolysis, red cells rupture directly within the bloodstream, so hemoglobin floods into the plasma all at once; ③ the moment haptoglobin binds free Hb, the complex is cleared by the liver along with it; ④ haptoglobin is exhausted within a short time and becomes rapidly undetectable in blood, and free Hb also leaks through the glomerulus into the urine, causing hemoglobinuria; ⑤ in extravascular hemolysis, by contrast, red cells are engulfed whole and digested by splenic macrophages, so hemoglobin never leaks into the plasma and haptoglobin barely falls. One marker localizes it all: an undetectable haptoglobin means intravascular.

Hereditary spherocytosis (HS) is the licensing exam's favorite case of extravascular hemolysis — a reversed trap frequently mislabeled as intravascular. The clues: an autosomal dominant family history, jaundice, gallstones, spherocytes on smear (lacking the central pallor), an elevated MCHC, and increased osmotic fragility; the modern first-choice diagnostic test is the EMA (eosin-5-maleimide) binding assay, more sensitive and specific than osmotic fragility testing. Its Coombs' test is negative (it is not autoimmune) — precisely the watershed separating it from AIHA (autoimmune hemolytic anemia), which likewise shows spherocytes but is Coombs-positive. Treatment for HS is splenectomy — the spleen is the site of destruction, and removing it relieves the hemolysis (it does not correct the membrane defect); but at least 2 weeks before splenectomy, the patient must receive encapsulated-organism vaccines (pneumococcus, Hib, meningococcus), and postoperative sepsis risk must be watched for.

Three Classic Clinical Anemias: Stringing Every Clue Together by Mechanism

Pernicious anemia: a special form of B12 deficiency caused by anti-parietal cell antibodies / anti-intrinsic factor antibodies → intrinsic factor deficiency → impaired B12 absorption, often accompanied by atrophic gastritis. Presentation: a smooth, inflamed tongue (glossitis), a markedly elevated MCV (>110), and leukocytes and platelets that may also fall (pancytopenia). One detail that is easy to get wrong — the erythroid precursors in the marrow are actually "increased," not decreased, but because DNA synthesis is stalled, the marrow makes plenty of red cell precursors yet cannot export them, a state called ineffective erythropoiesis; the periphery therefore remains anemic, and both LDH and indirect bilirubin rise (these cells die right there in the marrow).

Severe β-thalassemia (β-thalassemia major): a defect in β-globin chain synthesis → ineffective erythropoiesis plus hemolysis → severe anemia. The core of treatment is hypertransfusion, keeping hemoglobin at a higher target (roughly above 9–10.5 g/dL) — the purpose is not merely to replace blood but to suppress the marrow's compensatory hyperplasia and prevent extramedullary hematopoiesis (hepatosplenomegaly, skeletal deformity, and the "hair-on-end" skull appearance). The price is iron overload, so an iron chelator is required at the same time; definitive cure requires hematopoietic stem cell transplantation.

The transfusion logic of severe β-thalassemia: transfuse "high enough" and the marrow finally "falls silent" — only then does extramedullary hematopoiesis stop acting up.

Paroxysmal nocturnal hemoglobinuria (PNH): the archetypal disease of intravascular hemolysis. The mechanism is a somatic PIGA gene mutation, which leaves the hematopoietic stem cell unable to synthesize a GPI anchor, so the cell membrane loses CD55 and CD59 — the two brakes on complement attack. Without these brakes, complement drills holes in the red cell membrane continuously, producing chronic intravascular hemolysis. The triad: hemolytic anemia, thrombosis (the leading cause of death), and a tendency toward marrow failure. Diagnosis relies on flow cytometry demonstrating loss of CD55/CD59 (or the more sensitive FLAER assay detecting the GPI anchor); treatment is the complement inhibitor eculizumab.

Aplastic Anemia and Fetal Hemoglobin

Severe acquired aplastic anemia is the marrow "going on strike entirely," so all three lineages fall (pancytopenia), the RPI is low, and marrow examination shows a hypocellular marrow (fat replacing hematopoietic tissue). Its standard treatment is immunosuppression with ATG (antithymocyte globulin) plus cyclosporine; for a young patient with a suitably HLA-matched donor, allogeneic bone marrow transplant is the first choice. Steroids alone are not first-line — a trap frequently chosen in error.

The developmental sequence of fetal hemoglobin is also frequently tested: in the earliest embryonic period (the yolk-sac stage), the embryonic hemoglobins Gower I, Gower II, and Portland appear; by roughly 10–11 weeks, the dominant hemoglobin is HbF (α2γ2); after birth, this gradually converts to HbA (α2β2). So the answer to "what is the dominant hemoglobin at 10–11 weeks" is HbF, not one of the Gower hemoglobins.

⭐ Board-exam essentials

The Two Axes of Anemia — Must-Know Checklist

First cut, MCV: for microcytic anemia, ferritin separates IDA (↓) from ACD (normal/↑); thalassemia is identified by a Mentzer index <13, HbA2 >3.5%, and iron that is not deficient but overloaded.
Macrocytic: B12/folate plus a hypersegmented neutrophil; only B12 deficiency causes neurologic findings; folate alone masks the neurologic catastrophe of B12 deficiency.
Second cut, RPI: >2–3 = marrow compensation (hemolysis/blood loss); <2 = inadequate production.
Localizing hemolysis: intravascular = haptoglobin↓↓ + hemoglobinuria (PNH, ABO incompatibility, G6PD crisis); extravascular = splenic phagocytosis (HS, AIHA, thalassemia).
HS = autosomal dominant + spherocytes + MCHC↑ + Coombs(−); first-choice diagnosis is the EMA test; treatment is splenectomy (vaccinate against encapsulated organisms 2 weeks beforehand). HS is extravascular hemolysis (the reversed trap).
Pernicious anemia: anti-parietal cell/anti-intrinsic factor antibodies, glossitis, marrow erythroid precursors increased but ineffective.
β-thalassemia major: hypertransfusion suppresses extramedullary hematopoiesis; iron overload requires a chelator.
PNH: PIGA mutation → loss of CD55/CD59 → intravascular hemolysis; the leading cause of death is thrombosis; treatment is eculizumab.
Aplastic anemia: standard treatment is ATG + cyclosporine; steroids alone are not first-line.
The dominant hemoglobin at 10–11 weeks = HbF (α2γ2); the Gower hemoglobins are the earlier embryonic forms.
Traps: labeling HS as intravascular hemolysis; treating thalassemia as iron deficiency and giving iron; masking B12 neurologic symptoms by replacing folate alone; reflexively giving IV vitamin K for a high INR without bleeding; reading the raw reticulocyte percentage directly as the RPI.

♪ Sing-along text — English rendering of the Mandarin song lyrics

🎵 Chapter song　血液腫瘤・貧血的雙軸偵探Spotify Apple Music

Alternate take (Version B): Spotify · Apple Music

Sung in Mandarin by Otter Whistle · album 《醫學國考・血液腫瘤》 · the text below is an English rendering of the lyrics

Anemia looks bewildering at first, but it really rests on only two axes: one, the mean corpuscular volume, tells you whether the red cell grew the way it should; the other, the reticulocyte count and production index, tells you whether the marrow is trying. Make these two cuts first, and most questions already have their cause pinned down. Why does MCV triage so cleanly? Because it reflects whether the red cell actually grew correctly. When iron is deficient, hemoglobin cannot be made, so the cell neither grows large nor stains deeply — hence microcytic, hypochromic. When vitamin B12 or folate is deficient, DNA synthesis stalls, and nuclear division cannot keep up with cytoplasmic growth, so the marrow progenitor grows into an oversized cell whose DNA has fallen behind — on the periphery, this is macrocytic anemia. A normal size usually means the marrow itself has no problem, but the cells are either being lost through bleeding, being destroyed, or the marrow itself is on strike — and this is where the second axis takes over.

Two axes triage every anemia: MCV asks if the red cell grew right, the production index asks if the marrow is trying — and the question sorts itself out.

Both iron deficiency anemia and anemia of chronic disease can be microcytic, and the key discriminator is ferritin. Iron deficiency means the body is genuinely depleted of iron, so ferritin falls, and the deficiency forces the liver to compensate by making more transferrin, so the total iron-binding capacity actually rises. Anemia of chronic disease, by contrast, is inflammation raising hepcidin and locking iron inside macrophages so it cannot escape, so ferritin stays normal or even rises while the total iron-binding capacity falls. Ferritin is the only marker that actually falls in iron deficiency, and that is the cleanest watershed between the two. Thalassemia is also microcytic, but its nature is entirely different — a defect in globin chain synthesis causing ineffective erythropoiesis plus hemolysis, with iron status usually normal or even overloaded, especially in the chronically transfused, where the concern is iron overload rather than the need for more iron. The discriminating tool is the Mentzer index, mean corpuscular volume divided by the red cell count: below thirteen favors thalassemia, above thirteen favors iron deficiency, because the red cell count in thalassemia is often not low and the red cell distribution width is usually normal. Finally, hemoglobin electrophoresis confirms it — in β-thalassemia, an HbA2 above three point five percent secures the diagnosis.

The most common cause of macrocytic anemia is deficiency of vitamin B12 or folate, and a neutrophil hypersegmented beyond five lobes on smear is the hallmark. To tell B12 deficiency from folate deficiency, look at the neurologic findings — only B12 deficiency causes subacute combined degeneration; folate deficiency does not. Here lies a major clinical trap: giving folate alone can correct the hematologic picture while the neurologic damage of B12 deficiency continues to worsen underneath and eventually becomes permanent. So whenever macrocytic anemia appears, you must check both B12 and folate first, or replace both together — never reflexively give folate alone.

Two axes triage every anemia: MCV asks if the red cell grew right, the production index asks if the marrow is trying — and the question sorts itself out.

The second axis is the production index. Looking at the raw reticulocyte percentage alone is misleading because it is diluted by the hematocrit, so it must be corrected into the production index — the formula is the reticulocyte percentage multiplied by the patient's hematocrit divided by forty-five, then divided again by a maturation correction factor, which takes a value of two at a hematocrit of twenty-three. An index above two to three means good marrow compensation — cells are being destroyed or lost, but the marrow is working hard to restock — typically hemolysis or blood loss; below two means inadequate production, typically nutrient deficiency, aplastic anemia, or marrow infiltration. Only once you have pinned down the production index do you earn the right to ask where the hemolysis is actually happening.

Hemolysis splits into intravascular and extravascular, and the difference is simply where the red cell breaks. Intravascular hemolysis is a red cell rupturing directly within the vessel, leaking hemoglobin into the plasma; haptoglobin, the scavenger protein the liver makes to capture free hemoglobin, binds it and is dragged along to the liver for breakdown, so in intravascular hemolysis haptoglobin is consumed until it becomes undetectable, and hemoglobinuria appears as well. Extravascular hemolysis is splenic macrophages engulfing the abnormal red cell whole, so hemoglobin never leaks into the plasma and haptoglobin barely falls. The representative diseases split just as cleanly — intravascular includes paroxysmal nocturnal hemoglobinuria, ABO-incompatible transfusion, and acute G6PD crises; extravascular includes hereditary spherocytosis, autoimmune hemolysis, and thalassemia. Note that hereditary spherocytosis, despite sounding dramatic with its spherocytes, is actually extravascular hemolysis — a reversed trap.

The clues to hereditary spherocytosis are an autosomal dominant family history, jaundice, gallstones, spherocytes lacking central pallor on smear, an elevated mean corpuscular hemoglobin concentration, and increased osmotic fragility; the modern first-choice diagnosis is the eosin-5-maleimide binding test. Its Coombs test is negative, and that is precisely the watershed separating it from autoimmune hemolysis, which likewise shows spherocytes but is Coombs-positive. Treatment is splenectomy, because the spleen is the site of destruction and removing it relieves the hemolysis — but at least two weeks before splenectomy the patient must receive encapsulated-organism vaccines against pneumococcus, Haemophilus influenzae, and meningococcus, and postoperative sepsis risk must be watched.

Two axes triage every anemia: MCV asks if the red cell grew right, the production index asks if the marrow is trying — and the question sorts itself out.

Pernicious anemia is a special form of B12 deficiency, caused by autoimmune anti-parietal cell or anti-intrinsic factor antibodies leading to intrinsic factor deficiency and an inability to absorb B12. It presents with a smooth, inflamed tongue, a mean corpuscular volume clearly above one hundred ten, and leukocytes and platelets that can fall together as well. One point that is easy to get wrong is that the red cell precursors in the marrow are actually increased rather than decreased — but because DNA synthesis is stalled, the marrow makes plenty of them yet cannot export them, a state of ineffective erythropoiesis, so the periphery remains anemic and these cells die right there in the marrow, driving up both lactate dehydrogenase and indirect bilirubin. The transfusion logic of severe β-thalassemia is not simply replacing blood but suppressing the marrow — transfuse high enough and the marrow finally falls silent, so extramedullary hematopoiesis stops acting up and hepatosplenomegaly and the hair-on-end skull do not appear; the price is iron overload, which requires a chelator given at the same time.

Paroxysmal nocturnal hemoglobinuria is the archetype of intravascular hemolysis: the mechanism is a somatic PIGA mutation that leaves the hematopoietic stem cell unable to synthesize a GPI anchor, so the cell membrane loses the complement brakes CD55 and CD59, and complement drills holes in the red cell membrane continuously, producing chronic intravascular hemolysis. The triad is hemolysis, thrombosis, and a tendency toward marrow failure, and the leading cause of death is not the anemia but the thrombosis. Diagnosis relies on flow cytometry to detect loss of CD55 and CD59, or the more sensitive FLAER assay, and treatment is the complement inhibitor eculizumab. Last comes aplastic anemia, where the marrow goes on strike entirely and all three lineages fall; the standard treatment is immunosuppression with antithymocyte globulin plus cyclosporine, and for a young patient with a suitable donor, allogeneic bone marrow transplant is the first choice — steroids alone are not first-line. The sequence of fetal hemoglobin is also frequently tested: the earliest embryonic hemoglobins are Gower I, Gower II, and Portland; by roughly ten to eleven weeks, the dominant hemoglobin is fetal hemoglobin, built from two α chains and two γ chains, and only after birth does it gradually convert to adult hemoglobin. Hold the two axes of this chapter — mean corpuscular volume and the production index — and every anemia question can be reasoned through in turn.

🌙 On-call challenge — take this chapter's patient in English (OET Station 2) →

3. Leukemia's Four Quadrants: From the Philadelphia Chromosome to the APL Emergency

Leukemia questions are numerous and look scattered, but once you place them on the four-quadrant map of "acute/chronic × myeloid/lymphoid," ninety percent of them find their own place.

The Four Quadrants: Localize First, Then Interpret

	Myeloid	Lymphoid
Acute (rapid progression, blasts↑)	Acute myeloid leukemia (AML) (mostly adults; Auer rods, MPO+; M3 = APL)	Acute lymphoblastic leukemia (ALL) (the most common childhood cancer; TdT+, MPO−)
Chronic (slow progression, mature cells↑)	Chronic myeloid leukemia (CML) (BCR-ABL, t(9;22) Philadelphia chromosome)	Chronic lymphocytic leukemia (CLL) (elderly, mature small lymphocytes, smudge cells)

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

🔬 Mechanism, unpacked

The core logic of this table is "where the cell line gets stuck." Break the causal chain into five steps: ① normal hematopoiesis is an assembly line running from precursor cells to mature cells; ② acute leukemia is an early cell on some differentiation pathway getting stuck, so blasts explode in number and progression is rapid; ③ chronic leukemia is a pathway that is not completely blocked — some station simply begins proliferating out of control, so cells of every maturation stage remain visible, only in explosively increased numbers, with slow progression; ④ the acute blast threshold is set at ≥20% of the marrow, a diagnostic number; ⑤ add one more layer of lineage clues and the diagnosis locks in: Auer rods plus MPO positivity mean myeloid, TdT positivity with MPO negativity means lymphoid. Localize the quadrant first, then match the clues, and nothing gets confused.

Myeloid or lymphoid — check two quick clues: Auer rods (slender rod-shaped crystals) plus myeloperoxidase (MPO) positivity → AML (myeloid); MPO negative, TdT positive → ALL (lymphoid). An Auer rod is ironclad proof of myeloid lineage, because it is nothing but a crystallized form of myeloid (azurophilic) granules.

CML: The Textbook Case of the Philadelphia Chromosome and Targeted Therapy

🔬 Mechanism, unpacked

The mechanism of CML runs in a single line — break the causality into five steps: ① t(9;22) fuses ABL1 from chromosome 9 onto BCR on chromosome 22, forming the Philadelphia chromosome; ② the BCR-ABL1 fusion gene produces the p210 fusion protein, whose tyrosine kinase is "locked permanently on"; ③ this continuously active kinase keeps driving myeloid cells to proliferate, like an engine with the accelerator pinned to the floor; ④ myeloid cells at every maturation stage are churned out in excess, the white count soars into the hundreds of thousands, the spleen becomes massive, and the LAP score falls; ⑤ imatinib, a BCR-ABL tyrosine kinase inhibitor (TKI), plugs this switch with precision, freezing most patients in the chronic phase — which is exactly why it is the most classic example of "targeted therapy."

Test	Finding in CML	Role
Bone marrow karyotype	t(9;22)	Key
Peripheral blood BCR/ABL	(+); quantitative levels allow long-term monitoring	Key
LAP score (leukocyte alkaline phosphatase)	Low/decreased	Distinguishes from a leukemoid reaction (in which LAP is high)
Immunophenotyping	—	The single least necessary test for confirming CML (that tool belongs to acute leukemia)

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

Clinically, the course of CML divides into three stages — chronic phase → accelerated phase → blast crisis — and TKIs freeze most patients in the chronic phase.

The LAP score in CML is low — pair it in memory with "a leukemoid reaction has a high LAP," or the direction will flip on you.

Two frequently tested traps: radiation is in fact a CML risk factor — most patients have no identifiable trigger, but CML clearly increases in atomic-bomb survivors and after radiotherapy, making ionizing radiation its one established environmental risk factor; and the single least necessary test for confirming CML is immunophenotyping — that tool sorts out the lineage of acute leukemia, whereas chronic CML is adequately confirmed by cell morphology and genetic testing alone.

Pediatric ALL: The Reasoning Chain Behind Childhood's Most Common Cancer

Diagnosis: bone marrow examination showing blasts ≥ 20%; flow-cytometric immunophenotyping plus cytogenetic classification. Prognostic factors are the licensing exam's single highest-yield topic here:

Favorable prognosis	Unfavorable prognosis
Age 1–10 years	<1 year (infant) or ≥10 years
Presenting WBC <50,000/μL	WBC ≥50,000/μL
Hyperdiploidy, ETV6-RUNX1 (t(12;21))	BCR-ABL (t(9;22), Ph+), KMT2A (MLL) rearrangement, hypodiploidy
Good early chemotherapy response, MRD-negative	MRD-positive

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

A few directions not to flip: the Philadelphia chromosome (t(9;22)) is unfavorable in ALL (an entirely different role from the one it plays in CML — don't transplant it to the wrong spot); Ph(+) ALL is more common in adults (roughly 20–25%), and only 3–5% in children — "children have a higher rate of Ph(+)" is a false statement. For Ph(+) ALL, treatment adds a TKI (imatinib/dasatinib) on top of chemotherapy.

CNS prophylaxis is another frequently tested detail: leukemic cells readily hide in the CNS (chemotherapy penetrates the blood-brain barrier poorly), so every case of ALL requires CNS prophylaxis. First-line is intrathecal chemotherapy by lumbar puncture (intrathecal methotrexate); cranial radiation has been demoted to second-line (owing to cognitive impairment and the risk of secondary tumors), reserved for high-risk disease or existing CNS involvement. An important trap here: imatinib's penetration into the cerebrospinal fluid is extremely low (CSF/plasma <1%) and cannot serve as CNS prophylaxis (dasatinib's CNS penetration is somewhat better) — so even when Ph(+) ALL is treated with a TKI, intrathecal chemotherapy must still be given; don't skip it.

APL (AML-M3): Give ATRA the Moment You Suspect It

🔬 Mechanism, unpacked

The core mechanism of APL breaks into five steps: ① t(15;17) fuses PML from chromosome 15 onto RARA on chromosome 17, forming the PML-RARA fusion gene; ② this fusion protein blocks normal retinoic acid signaling, arresting the differentiation of the promyelocyte, so the cells all halt at this stage and cannot mature; ③ the promyelocyte's cytoplasm is packed with granules containing tissue factor, releasing procoagulant material in bulk; ④ at the same time, overexpression of annexin II activates plasminogen, so the patient develops disseminated intravascular coagulation (DIC) together with primary hyperfibrinolysis — the hallmark being prolonged PT/aPTT, falling fibrinogen, rising D-dimer, and a bleeding tendency; ⑤ ATRA (all-trans retinoic acid) lifts the differentiation block, forcing the promyelocyte to continue maturing, so granule release falls and the DIC recedes with it — which is why giving ATRA the moment it is suspected is what saves the patient's life.

For this reason, APL carries one life-saving rule: the moment APL is clinically suspected, "give ATRA first" — there is no need to wait for genetic confirmation. ATRA forces the promyelocyte to mature, pushing the cell forward, so granule release falls and the DIC recedes along with it. At the same time, aggressively transfuse platelets and cryoprecipitate/FFP to correct the coagulopathy. Standard treatment is ATRA + ATO (arsenic trioxide); low-/intermediate-risk patients can use a chemo-free ATRA + ATO regimen, while high-risk patients add an anthracycline.

Two traps worth remembering: ATRA monotherapy can induce remission but, without consolidation, relapses easily, and it readily triggers differentiation syndrome — fever, weight gain, pulmonary infiltrates, respiratory distress, hypotension, and pleural/pericardial effusion. Management is corticosteroids (dexamethasone), with ATRA held temporarily if needed; standard therapy must combine ATRA with ATO or chemotherapy. In addition, early treatment must also guard against tumor lysis syndrome (TLS): hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia — prevention relies on hydration plus allopurinol, with rasburicase for high-risk or established cases (contraindicated in G6PD deficiency).

CLL: Prognostic Stratification — Don't Mistake Anemia for a Good Sign

CLL is the most common chronic leukemia of the elderly, typically presenting with lymphocytic leukocytosis and smudge cells on smear (fragile mature lymphocytes crushed during smear preparation). Its clinical staging (Rai/Binet) follows one clear direction: patients with anemia or thrombocytopenia (advanced stage) have a worse prognosis and a shorter median survival; early-stage patients without anemia (Rai 0) have a better prognosis, reaching 10 years or more. So "patients with anemia have a better prognosis" reverses the direction and is wrong.

The cytogenetic prognosis (by FISH) lines up from best to worst:

Isolated del(13q) (best) > normal karyotype > trisomy 12 > del(11q) > del(17p) (worst, involving TP53)

del(17p) carries the worst prognosis because it deletes TP53 (the principal tumor-suppressor brake), and it also responds worst to conventional chemoimmunotherapy; these patients generally need newer agents such as BTK inhibitors or BCL-2 inhibitors.

⭐ Board-exam essentials

Leukemia's Four Quadrants — Must-Know Checklist

Four quadrants: acute/chronic × myeloid/lymphoid. Auer rods + MPO+ = AML; TdT+ MPO− = ALL; acute blast threshold ≥ 20%.
CML = t(9;22) BCR-ABL + low LAP + imatinib; radiation is in fact a CML risk factor; immunophenotyping is the least necessary test for diagnosis.
ALL prognosis: Ph(+) is unfavorable in ALL (don't transplant CML's role onto it); Ph(+) is more common in adults than children; hyperdiploidy/ETV6-RUNX1 are favorable; KMT2A rearrangement is unfavorable.
ALL CNS prophylaxis = intrathecal chemotherapy (intrathecal MTX) is first-line; cranial radiation is second-line; imatinib does not cross into the CSF and cannot replace intrathecal chemotherapy.
APL = t(15;17) PML-RARA; give ATRA the moment it is suspected (life-saving); standard therapy is ATRA + ATO; ATRA alone relapses easily; both ATRA and ATO can cause differentiation syndrome (managed with dexamethasone).
APL's hallmark = DIC + primary hyperfibrinolysis; guard against TLS early in treatment (rasburicase; contraindicated in G6PD deficiency).
CLL: anemia/thrombocytopenia = advanced stage = worse prognosis (don't reverse the direction); by FISH, del(13q) is best, del(17p) is worst (TP53).
Traps: treating the Philadelphia chromosome as favorable in ALL (it is actually unfavorable); claiming CML is unrelated to radiation (ionizing radiation is in fact an established risk factor); assuming that giving a TKI in Ph(+) ALL excuses you from CNS prophylaxis (imatinib does not cross into the CSF); withholding ATRA in APL until the genetic report returns (missing the life-saving window); treating anemia in CLL as a favorable sign (it actually signals advanced disease).

♪ Sing-along text — English rendering of the Mandarin song lyrics

🎵 Chapter song　血液腫瘤・白血病四象限Spotify Apple Music

Alternate take (Version B): Spotify · Apple Music

Sung in Mandarin by Otter Whistle · album 《醫學國考・血液腫瘤》 · the text below is an English rendering of the lyrics

Leukemia questions are numerous and look scattered, but once you place them on the four-quadrant map of acute versus chronic crossed with myeloid versus lymphoid, ninety percent of them find their own place. Acute leukemia is an early cell on some differentiation pathway getting stuck, so blasts explode in number and progression is rapid; chronic leukemia is a pathway that is not completely blocked, where some station simply begins proliferating out of control, so you see cells of every maturation stage, only in explosively increased numbers, with slow progression. The blast threshold for acute leukemia is twenty percent of the marrow, a diagnostic number, and myeloid versus lymphoid is separated simply by checking Auer rods and myeloperoxidase — an Auer rod is nothing but a crystallized form of myeloid azurophilic granules, and positivity means acute myeloid leukemia, while negativity together with positive terminal deoxynucleotidyl transferase means acute lymphoblastic leukemia.

Four quadrants locate everything: acute versus chronic by the blasts, myeloid versus lymphoid by the Auer rod, and the targeted drug plugs the broken accelerator of the Philadelphia chromosome.

The story of chronic myeloid leukemia is the cleanest of all: the Philadelphia chromosome is simply a translocation between chromosomes nine and twenty-two producing the BCR-ABL fusion gene, which makes a fusion protein called p210 carrying continuously active tyrosine kinase activity — an accelerator stuck permanently down — so myeloid cells proliferate out of control. Imatinib was the first tyrosine kinase inhibitor marketed against BCR-ABL, plugging this accelerator switch with precision, which is exactly why it is the most classic example of targeted therapy. Clinically, the course of chronic myeloid leukemia divides into a chronic phase, an accelerated phase, and blast crisis, and tyrosine kinase inhibitors freeze most patients in the chronic phase. Among the diagnostic tools, remember that the leukocyte alkaline phosphatase score is low — precisely the opposite of the high score seen in a leukemoid reaction, which lets the two be distinguished. Two traps are worth remembering: first, do not claim chronic myeloid leukemia is unrelated to radiation — most patients have no identifiable trigger, but ionizing radiation is its one established environmental risk factor, as seen in atomic-bomb survivors and after radiotherapy; second, the single least necessary test for confirming chronic myeloid leukemia is immunophenotyping, a tool used to sort the lineage of acute leukemia, since chronic disease is adequately confirmed by karyotype and PCR alone.

Childhood acute lymphoblastic leukemia is the most common malignancy of childhood, most often of the B-cell precursor type; the mechanism is malignant proliferation of a lymphoid precursor cell displacing normal marrow, so pancytopenia from suppression of all three lineages appears together with bone pain, hepatosplenomegaly, and lymphadenopathy, and the disease is especially fond of spreading to the central nervous system and the testes. The most important prognostic factors are age and the white count at diagnosis: one to ten years old with a white count under fifty thousand carries a good prognosis, while an infant under one year or a child ten or older, or a white count above fifty thousand, carries a poor one; cytogenetically, hyperdiploidy and the twelve-twenty-one translocation producing ETV6 plus RUNX1 carry the best prognosis, while the Philadelphia chromosome, KMT2A rearrangement, and hypodiploidy carry the worst.

Four quadrants locate everything: acute versus chronic by the blasts, myeloid versus lymphoid by the Auer rod, and the targeted drug plugs the broken accelerator of the Philadelphia chromosome.

The role of the Philadelphia chromosome in acute lymphoblastic leukemia is entirely different from its role in chronic myeloid leukemia: in the latter, it is the disease itself; in the former, it is merely a marker of poor prognosis — don't transplant this role to the wrong place. Another frequently tested angle on Philadelphia-positive acute lymphoblastic leukemia is that it accounts for roughly twenty to thirty percent of cases in adults but only three to five percent in children, so the claim that children have a higher rate of Philadelphia positivity is false — adults actually have the higher rate. Treatment for these patients adds a tyrosine kinase inhibitor on top of chemotherapy, but there is a critically important trap here: imatinib's penetration into the cerebrospinal fluid is under one percent, so it simply cannot be used for central nervous system prophylaxis or treatment — meaning that even with a tyrosine kinase inhibitor on board, intrathecal chemotherapy must still be given; don't skip it. Every case of acute lymphoblastic leukemia requires central nervous system prophylaxis, with intrathecal methotrexate as first-line; cranial radiation has been demoted to second-line because of cognitive impairment and the risk of secondary tumors, reserved only for high-risk patients or those with existing central nervous system involvement.

Four quadrants locate everything: acute versus chronic by the blasts, myeloid versus lymphoid by the Auer rod, and the targeted drug plugs the broken accelerator of the Philadelphia chromosome.

Acute promyelocytic leukemia is the M3 subtype of acute myeloid leukemia: the fifteen-seventeen translocation produces the PML-RARA fusion, arresting promyelocyte differentiation at this stage, and the cytoplasm fills with granules containing tissue factor, which are released in bulk to trigger disseminated intravascular coagulation together with primary hyperfibrinolysis — hence the hallmark of prolonged prothrombin time and partial thromboplastin time, falling fibrinogen, rising D-dimer, and a bleeding tendency, with early intracranial or pulmonary hemorrhage as the leading cause of death. For this reason, the disease carries one life-saving rule: give all-trans retinoic acid the moment it is clinically suspected, without waiting for the genetic report, because all-trans retinoic acid forces the promyelocyte to mature, so granule release falls and the disseminated intravascular coagulation recedes with it; at the same time, aggressively transfuse platelets, cryoprecipitate, and fresh frozen plasma to correct the coagulopathy. Standard therapy is all-trans retinoic acid plus arsenic trioxide; low- and intermediate-risk groups may use a chemotherapy-free regimen, while high-risk groups add an anthracycline. All-trans retinoic acid alone can induce remission but relapses easily without consolidation, and it readily triggers differentiation syndrome, presenting with fever, weight gain, pulmonary infiltrates, respiratory distress, hypotension, and serosal effusions; management is corticosteroids, holding all-trans retinoic acid temporarily as needed. Early treatment must also guard against tumor lysis syndrome — hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia — prevented with hydration plus allopurinol, with rasburicase for high-risk cases, though it is contraindicated in G6PD deficiency. Finally, keep the direction straight for chronic lymphocytic leukemia: anemia or a low platelet count means advanced disease and a worse prognosis — never mistake anemia for a favorable sign; cytogenetically, an isolated 13q deletion is best, and a 17p deletion is worst because it discards the tumor-suppressor brake p53. Hold this chapter's two throughlines — the four quadrants and targeted therapy — and everything from the Philadelphia chromosome to the life-saving rule for acute promyelocytic leukemia follows the same logic: which cell, stuck at which stage, broken by what.

🌙 On-call challenge — take this chapter's patient in English (OET Station 3) →

4. Lymphoma and Myeloma: From Reed-Sternberg Cells to CRAB

Lymphoma and myeloma are both malignant expressions of the B-cell family, but the former is cells running out of control within the lymph node, while the latter is a monoclonal expansion of plasma cells within the bone marrow — their clinical presentations could not be more different.

Hodgkin vs. Non-Hodgkin: Sorting the Big Picture First

Feature	Hodgkin lymphoma (HL)	Non-Hodgkin lymphoma (NHL)
Hallmark cell	Reed-Sternberg cell (arising from a B lymphocyte); CD15+/CD30+, CD45−	Heterogeneous; most commonly diffuse large B-cell lymphoma (DLBCL)
Pattern of spread	Contiguous, spreading to adjacent lymph nodes	Discontinuous ("skipping"), prone to extranodal involvement
Age	Bimodal (young + elderly)	Rises with age
Prognosis	Curable in most cases	Depends on the subtype

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

The Reed-Sternberg cell, with its binucleate "owl-eye" appearance, is the hallmark of HL; it arises from a B cell, is CD15+/CD30+, and is CD45−.

HL is associated with EBV, and contiguous spread along the lymph nodes is its signature — precisely why HL staging can use anatomic location to predict prognosis so cleanly, whereas the discontinuous spread of NHL makes this far less clear-cut.

DLBCL: The Most Common NHL and the Reasoning Chain Behind R-CHOP

Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive NHL in adults, yet it is curable. Standard treatment is R-CHOP: Rituximab + Cyclophosphamide + Hydroxydaunorubicin (doxorubicin) + Oncovin (vincristine) + Prednisone.

But rituximab carries a frequently tested adverse-effect trap: rituximab (anti-CD20) therapy → reactivation of the JC virus → progressive multifocal leukoencephalopathy (PML). The mechanism is suppression of B cells and immune surveillance, allowing latent JC virus to seize the opportunity and attack the central nervous system's oligodendrocytes; clinically this shows up as progressive neurologic deficits and white-matter lesions on MRI. Whenever you see "neurologic symptoms plus white-matter lesions on MRI after rituximab therapy," answer PML.

Chromosomes and Fusion Genes: The Fingerprints of Each NHL Subtype

The frequently tested reasoning chain for each NHL subtype — "chromosome → cell morphology → immunophenotype → clinical picture":

Lymphoma	Chromosome/fusion	Mechanism/features
Burkitt lymphoma	t(8;14) → c-MYC	A "starry sky" pattern (tingible-body macrophages), Ki-67 near 100%; the endemic form is linked to EBV
Follicular lymphoma	t(14;18) → BCL-2	Anti-apoptotic → indolent but hard to cure
Mantle cell lymphoma	t(11;14) → Cyclin D1 (BCL-1)	CD5+ but CD23− (the crux of distinguishing it from CLL)
Anaplastic large cell lymphoma (ALCL)	Of T-cell origin	CD30+, often ALK+, with hallmark cells; derived from cytotoxic T cells
Nasal NK/T-cell lymphoma	NK/T cell	CD56+, angiocentric vascular invasion and necrosis, EBV+, characteristically midline nasal

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

CD56 + vascular destruction + EBV + nasal = NK/T-cell lymphoma; CD30 + ALK = ALCL. Fix these two mnemonics in memory, and half the answer choices fall away.

The Immunophenotype Mnemonic for CLL: A B Cell Wearing a T-Cell Coat

CLL and SLL (small lymphocytic lymphoma) are two faces of the same disease — one in the blood, one in the lymph node. Its typical immunophenotype is CD20 (weak) + CD5+ + CD23+, alongside expression of the B-cell marker CD19.

Smudge cells are visible on smear — fragile mature lymphocytes crushed during smear preparation, leaving behind formless cellular shadows — one of the hallmark features of CLL.

Multiple Myeloma (MM): The Catastrophe of Monoclonal Plasma Cell Proliferation

🔬 Mechanism, unpacked

The entire presentation of MM can be derived from a single chain — break it into five steps: ① a single clone of plasma cells in the marrow undergoes malignant transformation and proliferates monoclonally; ② massive amounts of monoclonal immunoglobulin (M protein, often IgG) are secreted into the blood, and light chains (Bence-Jones protein) are also excreted in the urine; ③ malignant plasma cells activate osteoclasts, releasing large amounts of calcium and producing both hypercalcemia and osteolytic lesions (the C and the B); ④ light chains deposit in the renal tubules, compounded by dehydration from hypercalcemia, leading to renal failure (the R); ⑤ the marrow is crowded out by plasma cells, shrinking the space available for normal hematopoiesis and producing anemia (the A). The entire CRAB tetrad is simply the clinical expression of this one chain.

Diagnosis rests on the CRAB tetrad:

Letter	Meaning	Mechanism
C	hyperCalcemia	Osteoclast activation releasing calcium
R	Renal failure	Light-chain (Bence-Jones) deposition, hypercalcemia
A	Anemia	Marrow replaced by plasma cells
B	Bone lesions (osteolytic)	Osteoclast activation

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

Other clues: calcium↑, creatinine↑, Hb↓, ESR↑, rouleaux formation (red cells stacked like coins) on smear, plasma cell infiltration of the marrow, and compression collapse of the vertebrae.

MM carries two directional traps, one in imaging and one in treatment:

The imaging trap: skeletal assessment in MM uses X-ray (skeletal survey), low-dose CT, or MRI — all superior to a bone scan. Why? Because MM produces osteolytic lesions — osteoclast activity is brisk while osteoblast activity is not — and a bone scan detects osteoblastic activity, so it gives a false negative. Choosing a bone scan on this question is falling straight into the pit.

The treatment trap: MM's initial standard treatment is not high-dose intravenous chemotherapy. Initial therapy is usually a proteasome inhibitor (bortezomib) + an immunomodulatory drug (lenalidomide) + dexamethasone, with eligible patients proceeding to autologous HSCT.

Key Concepts in HSCT: GVHD, ABO, Autologous vs. Allogeneic

The testable points of hematopoietic stem cell transplantation cluster around "autologous vs. allogeneic" and "how ABO/HLA are handled."

Concept	Key point
Autologous HSCT	Uses the patient's own stem cells → no GVHD (no allogeneic immune attack); used for MM, lymphoma, and others
Allogeneic HSCT	From another donor → carries GVHD risk; but also brings a graft-versus-tumor effect
ABO incompatibility	In allogeneic transplant, ABO incompatibility does not require added immunosuppression or splenectomy (HLA is what actually drives rejection; ABO affects only the red-cell side and can be managed technically)
GVHD	Donor T cells attack the host; presents with rash, abnormal liver function, and diarrhea

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

HLA is what actually drives rejection (immune matching); ABO incompatibility affects only the red-cell side and requires no added immunosuppression or splenectomy — don't get this direction backward.

⭐ Board-exam essentials

Lymphoma, Myeloma, and Transplantation — Must-Know Checklist

HL's hallmark = the Reed-Sternberg cell (of B-cell origin, CD15+/CD30+ CD45−); contiguous spread; associated with EBV.
DLBCL = the most common NHL; standard therapy is R-CHOP (CD20+ → add rituximab).
rituximab → JC virus → PML (progressive multifocal leukoencephalopathy).
Chromosomes: Burkitt — t(8;14), c-MYC, starry sky, Ki-67 ≈ 100%; Follicular — t(14;18), BCL-2, anti-apoptotic; Mantle cell — t(11;14), Cyclin D1, CD5+CD23−.
ALCL = CD30+ ALK+, from cytotoxic T cells; nasal NK/T = CD56+ EBV+ with vascular invasion and necrosis.
CLL = CD20+CD5+CD23+ (a B cell wearing a T-cell coat); distinguished from mantle cell lymphoma (CD23−) by CD23.
MM = CRAB (hypercalcemia, renal failure, anemia, bone lesions) + M protein + rouleaux.
Image MM with X-ray/low-dose CT/MRI; a bone scan gives a false negative (osteolytic, with inactive osteoblasts).
MM's initial therapy is not high-dose chemotherapy; the standard is bortezomib + lenalidomide + dexamethasone → autologous HSCT.
Autologous HSCT carries no GVHD; in allogeneic transplant, ABO incompatibility needs no added immunosuppression or splenectomy (HLA is what actually drives rejection).
Traps: reversing the CD23 direction between CLL and mantle cell lymphoma; assessing MM with a bone scan (a false negative); starting MM treatment with high-dose chemotherapy; failing to think of PML when neurologic symptoms appear after rituximab; assuming autologous HSCT also carries GVHD risk.

♪ Sing-along text — English rendering of the Mandarin song lyrics

🎵 Chapter song　血液腫瘤・淋巴瘤與骨髓瘤Spotify Apple Music

Alternate take (Version B): Spotify · Apple Music

Sung in Mandarin by Otter Whistle · album 《醫學國考・血液腫瘤》 · the text below is an English rendering of the lyrics

Lymphoma and myeloma are both malignant expressions of the B-cell family: the former is cells running out of control within the lymph node, the latter a monoclonal expansion of plasma cells within the bone marrow, and their clinical presentations could not be more different. The hallmark of Hodgkin lymphoma is the binucleate, owl-eye-like Reed-Sternberg cell; it arises from a B cell yet carries a distinctive immunophenotype, positive for CD15 and CD30 but negative for CD45, and is linked to the Epstein-Barr virus. Contiguous spread along the lymph nodes is its signature, precisely why Hodgkin lymphoma staging can use anatomic location to predict prognosis so cleanly. The most common non-Hodgkin lymphoma is diffuse large B-cell lymphoma, whose standard treatment is R-CHOP, a combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. The reasoning chain runs straight through: diffuse large B-cell lymphoma is of B-cell origin and expresses CD20 on its surface, so adding the anti-CD20 agent rituximab lets R-CHOP pull the cure rate upward — one of the most successful examples anywhere of combining a targeted agent with cytotoxic chemotherapy.

See CD20, think rituximab; see CD56, think the nasal killer cell; see CRAB, think plasma cells.

rituximab carries a frequently tested adverse-effect trap: latent JC virus can reactivate after treatment and trigger progressive multifocal leukoencephalopathy, the mechanism being suppression of B cells and immune surveillance, which lets the JC virus seize the opportunity to attack the oligodendrocytes of the central nervous system, presenting clinically as progressive neurologic deficits plus white-matter lesions on MRI — see this clue and the answer is progressive multifocal leukoencephalopathy. The subtypes of non-Hodgkin lymphoma are tested along the reasoning chain from chromosome to cell morphology to immunophenotype to clinical picture. Burkitt lymphoma carries the eight-fourteen translocation driving overactivation of the c-MYC gene; the pathologic "starry sky" appearance comes from macrophages that have engulfed apoptotic cells sitting embedded within a dense background of tumor cells, with a proliferation index near one hundred percent, and the endemic form is linked to the Epstein-Barr virus. Follicular lymphoma carries the fourteen-eighteen translocation driving overexpression of BCL-2, which is anti-apoptotic, making it indolent yet hard to cure. Mantle cell lymphoma carries the eleven-fourteen translocation driving overexpression of cyclin D1, with an immunophenotype that is CD5-positive but CD23-negative — the crux of distinguishing it from chronic lymphocytic leukemia. Anaplastic large cell lymphoma arises from cytotoxic T cells, CD30-positive and often accompanied by ALK positivity. Nasal NK/T-cell lymphoma arises from natural killer or T cells, marked by CD56 positivity, vascular invasion and necrosis, and a link to the Epstein-Barr virus, characteristically occurring at the nasal midline — remember the mnemonic of CD56 plus vascular destruction plus EBV plus nasal, and the two are easily told apart.

The immunophenotype of chronic lymphocytic leukemia is weak CD20 expression together with positivity for both CD5 and CD23; the way to remember it is that it is a B cell wearing a T-cell coat, because CD5 properly belongs to T cells yet is, improperly, expressed on this population of B cells. Mantle cell lymphoma is likewise CD5-positive, so the discriminator is CD23: the former is CD23-positive, the latter CD23-negative and cyclin D1-positive — get the direction of this paired comparison backward and you lose the whole question. On smear, chronic lymphocytic leukemia also shows smudge cells, fragile mature lymphocytes crushed during smear preparation, leaving behind formless cellular shadows.

See CD20, think rituximab; see CD56, think the nasal killer cell; see CRAB, think plasma cells.

Multiple myeloma is the catastrophe of monoclonal malignant plasma cell proliferation: plasma cells in the marrow secrete a monoclonal immunoglobulin, the M protein, while simultaneously causing organ damage. Every clinical finding can be derived from this single chain, and diagnosis rests on the CRAB tetrad — hypercalcemia comes from activated osteoclasts releasing calcium, renal failure comes from deposition of light chains, that is, Bence-Jones protein, compounded by hypercalcemia, anemia comes from the marrow being replaced by plasma cells, and osteolytic lesions come from osteoclast activation; other clues include an elevated erythrocyte sedimentation rate, rouleaux formation on smear, plasma cell infiltration of the marrow, and compression collapse of the vertebrae. See elderly plus anemia plus low back pain plus poor renal function plus vertebral collapse, and think multiple myeloma immediately, not simple osteoporosis — this is its most typical face.

Multiple myeloma carries two directional traps that must be spelled out clearly. On imaging, skeletal assessment in multiple myeloma should use an X-ray skeletal survey, low-dose CT, or MRI, not a nuclear bone scan, because multiple myeloma produces osteolytic lesions with brisk osteoclast activity but inactive osteoblasts, and a nuclear bone scan detects osteoblastic activity, so it gives a false negative — choosing the bone scan on this question is falling straight into the pit. In treatment, the initial therapy for multiple myeloma is not high-dose intravenous chemotherapy but a triple combination of the proteasome inhibitor bortezomib, the immunomodulatory drug lenalidomide, and dexamethasone, with eligible patients proceeding afterward to autologous stem cell transplant.

See CD20, think rituximab; see CD56, think the nasal killer cell; see CRAB, think plasma cells.

Last comes the concept of hematopoietic stem cell transplantation. Autologous transplant uses the patient's own stem cells, so there is no graft-versus-host disease, and it is used for myeloma, lymphoma, and the like; allogeneic transplant comes from another person, carrying a risk of graft-versus-host disease, but also bringing the benefit of a graft-versus-tumor effect. A frequently tested angle is that blood-type incompatibility in allogeneic transplant does not require added immunosuppression or splenectomy, because what actually determines rejection is the human leukocyte antigen — blood type affects only the red-cell side and can be managed technically. Fix in memory that human leukocyte antigen is the true key to rejection, and the question will never mislead you. Graft-versus-host disease presents as donor T cells attacking the host, producing the three cardinal signs of rash, abnormal liver function, and diarrhea. Hold this chapter's two throughlines — the B-cell family and the plasma cell — and every distinction from R-CHOP to CRAB to hematopoietic stem cell transplantation can be reasoned through in turn.

🌙 On-call challenge — take this chapter's patient in English (OET Station 4) →

5. Bleeding and Coagulation: The PT/aPTT Coordinate System

The coordinate system for every coagulation question is simply the two axes of PT and aPTT. Memorize one coagulation-pathway diagram, and every question can be localized.

The Pathway Diagram: Draw the Coordinate System into Memory

Intrinsic pathway (aPTT): XII → XI → IX → VIII ┐

├→ X → V → II (thrombin) → fibrin (common pathway)

Extrinsic pathway (PT): VII (+ tissue factor) ─────┘

Test	Reflects	Prolongation indicates
PT	Extrinsic + common (VII, X, V, II, I)	VII deficiency, warfarin, liver disease, vitamin K deficiency
aPTT	Intrinsic + common (XII, XI, IX, VIII, X, V, II, I)	Hemophilia A (VIII)/B (IX), von Willebrand disease (VWD), heparin, lupus anticoagulant (LA)

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

🔬 Mechanism, unpacked

Why can this one diagram localize almost every bleeding question? Break the causal chain into five steps: ① each coagulation factor sits on only one pathway, so whichever factor is missing dictates which time is affected; ② factor VII travels only the extrinsic pathway, so VII deficiency or early warfarin therapy affects only the PT; ③ factors VIII and IX travel only the intrinsic pathway, so hemophilia A or B affects only the aPTT; ④ factors X, V, II, and I sit on the common pathway, so a deficiency of any of them prolongs both times together, which is why liver disease and DIC raise both; ⑤ one clue, one pathway — trace it to the end and you have identified exactly which factor is at fault. That is the secret behind localizing everything with just the two axes of PT and aPTT.

"aPTT prolonged, PT normal" is a problem of the intrinsic pathway — think first of hemophilia A/B, VWD, or lupus anticoagulant.

The Mixing Test: One Trick to Separate a Missing Factor from an Inhibitor

Once the aPTT is prolonged, the next step is to mix the patient's plasma with normal plasma at a 1:1 ratio and re-measure the aPTT. This one maneuver separates two entirely different diseases:

Result	Interpretation	Representative disease
Corrected (returns to normal)	Factor deficiency	Hemophilia A/B, VWD
Not corrected (remains prolonged)	An inhibitor (antibody) is present	Acquired hemophilia A (anti-VIII antibody), lupus anticoagulant

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

Hemophilia A: Congenital vs. Acquired, Different Bleeding Patterns

	Congenital hemophilia A	Acquired hemophilia A
Mechanism	X-linked inheritance, a Factor VIII gene defect	Autoantibodies against VIII (postpartum, autoimmune disease, malignancy, advanced age)
Population	Boys	Postpartum women, the elderly
Bleeding pattern	Hemarthrosis, deep intramuscular hematoma	Large skin ecchymoses, subcutaneous/soft-tissue hematoma (little joint bleeding)
Laboratory findings	aPTT↑, mixing corrects, VIII↓	aPTT↑, mixing does not correct, VIII↓, inhibitor titer (Bethesda units) positive
Treatment	Replace Factor VIII	Immunosuppression (corticosteroids ± cyclophosphamide/rituximab) to eliminate the antibody + a bypassing agent (rFVIIa, aPCC) for acute bleeds

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

Definition of severe hemophilia A: Factor VIII < 1%; moderate 1–5%; mild 5–40%.

Acquired hemophilia A carries one ironclad treatment rule: replacing high-dose VIII directly is often of limited benefit because the antibody neutralizes it, so a bypassing agent (such as rFVIIa or activated prothrombin complex concentrate) is used to control bleeding before the antibody has been cleared, while immunosuppression gradually drives the antibody down.

VWD: The Most Common Inherited Bleeding Disorder

Deficiency or dysfunction of vWF disrupts hemostasis at two levels: primary hemostasis — impaired platelet adhesion (because vWF is the essential bridge letting platelets stick to sites of endothelial injury); secondary hemostasis — vWF is the carrier protein for Factor VIII, so vWF↓ drags VIII↓ down with it.

So VWD's classic tetrad is: menorrhagia / mucosal bleeding + prolonged bleeding time + prolonged aPTT + normal PT. To distinguish VWD from hemophilia: VWD features mucosal bleeding plus a prolonged BT (platelet function is affected), whereas hemophilia is dominated by deep joint and muscle bleeding. Forgetting the prolonged aPTT (from the accompanying drop in VIII) is a common way to lose points.

Managing Anticoagulation and Thrombosis: Avoiding the Overtreatment Trap

Warfarin excess without bleeding (for example, INR 5.4):

INR / bleeding	Management
INR elevated, no bleeding	Hold warfarin / reduce the dose and observe (± low-dose oral vitamin K); IV vitamin K is not immediately needed
Severe bleeding	4-factor PCC (first choice) + IV vitamin K; FFP is second-choice

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

Reflexively giving IV vitamin K just because the INR is high — wrong. Over-reversal without bleeding actually puts patients with mechanical valves at risk of thrombosis; holding the dose or reducing it, with oral vitamin K, is the standard approach.

Acute peripheral arterial thrombosis: management is primarily catheter-directed thrombolysis or surgical thrombectomy/bypass, not systemic thrombolysis. Two reasons: systemic thrombolysis carries a high bleeding risk, and arterial thrombi are rich in platelets and fibrin, so local treatment is more effective.

Pseudothrombocytopenia: inside an EDTA collection tube, platelets clump together because of EDTA-induced agglutination, and the analyzer counts each clump as a single cell, falsely reporting "low" platelets — yet the patient has absolutely no clinical bleeding, which is the giveaway that it is spurious. The way to confirm it is to redraw into an EDTA-free tube such as sodium citrate, or to check the smear for platelet clumps; not a heparin tube (a heparin tube introduces its own coagulation interference).

One Paradox: Lupus Anticoagulant Prolongs Clotting In Vitro but Promotes Thrombosis In Vivo

Lupus anticoagulant is one of the antiphospholipid antibodies. In vitro, it interferes with phospholipid-dependent clotting assays (hence a prolonged aPTT with a mixing test that fails to correct), yet in vivo it actually promotes thrombosis — the paradox baked right into its name (called an "anticoagulant," yet it causes clots). Whenever you see "prolonged aPTT + recurrent thrombosis / miscarriage," think of it — and never mistake it for something that causes bleeding.

⭐ Board-exam essentials

Bleeding and Coagulation — Must-Know Checklist

PT reflects extrinsic + common; aPTT reflects intrinsic + common; "aPTT↑, PT normal = intrinsic pathway" (hemophilia A/B, VWD, LA).
Mixing test: corrects = a missing factor (hemophilia, VWD); does not correct = an inhibitor is present (acquired hemophilia, LA).
Congenital hemophilia A: hemarthrosis, boys, X-linked; treatment is replacing VIII; severe = VIII <1%.
Acquired hemophilia A: subcutaneous/soft-tissue ecchymoses, postpartum/elderly, anti-VIII antibodies; treatment is immunosuppression to clear the antibody + a bypassing agent (rFVIIa/aPCC); replacing VIII is often neutralized and ineffective.
VWD: BT↑ + aPTT↑ + PT normal; mucosal bleeding, menorrhagia.
Warfarin, high INR without bleeding = hold/reduce the dose and observe (no IV vitamin K); severe bleeding uses 4-factor PCC + IV vitamin K.
Acute arterial thrombosis = catheter-directed thrombolysis/surgery (not systemic thrombolysis).
Pseudothrombocytopenia = redraw into a sodium citrate (EDTA-free) tube; not a heparin tube.
The lupus anticoagulant paradox: aPTT↑ in vitro, yet thrombosis-prone in vivo.
Traps: treating acquired hemophilia as a simple deficiency and aggressively replacing VIII (it gets neutralized by the antibody); reflexively giving IV vitamin K for a high INR without bleeding (thrombosis risk in valve patients); switching to a heparin tube for pseudothrombocytopenia (it introduces its own coagulation interference); forgetting the prolonged aPTT in VWD; assuming the lupus anticoagulant causes bleeding (it actually promotes thrombosis).

♪ Sing-along text — English rendering of the Mandarin song lyrics

🎵 Chapter song　血液腫瘤・出血與凝血Spotify Apple Music

Alternate take (Version B): Spotify · Apple Music

Sung in Mandarin by Otter Whistle · album 《醫學國考・血液腫瘤》 · the text below is an English rendering of the lyrics

The coordinate system for every coagulation question is simply the two axes of prothrombin time and partial thromboplastin time, and memorizing one coagulation-pathway diagram lets every question be localized. The intrinsic pathway is reflected in the partial thromboplastin time, running from factor twelve through factor eleven, factor nine, and factor eight into the common pathway; the extrinsic pathway is reflected in the prothrombin time, running from factor seven plus tissue factor into the common pathway; the common pathway is factor ten, factor five, and factor two, that is, thrombin, continuing on to fibrinogen. Why can this one diagram localize almost every bleeding question? Because each coagulation factor sits on only one pathway — factor seven travels only the extrinsic pathway, so factor seven deficiency affects only the prothrombin time; factors eight and nine travel only the intrinsic pathway, so hemophilia affects only the partial thromboplastin time; while factors ten, five, two, and one sit on the common pathway, and a deficiency of any of them prolongs both times together. One clue, one pathway — trace it to the end and you have identified exactly which factor is at fault. So whenever you see a prolonged partial thromboplastin time with a normal prothrombin time, think first of hemophilia A or B, von Willebrand disease, or lupus anticoagulant.

Two axes localize every clot: see a prolonged PTT with a normal PT and think intrinsic pathway first; the mixing test corrects for missing, and fails to correct for blocked.

Once the partial thromboplastin time is prolonged, the next step is the mixing test, mixing the patient's plasma with normal plasma at a one-to-one ratio and re-measuring. The logic of this maneuver is exceptionally clean: normal plasma replenishes whatever factor is missing, so the aPTT returns to normal; but if an antibody is present, it neutralizes even the replenished factor, so the aPTT remains prolonged. One small maneuver separates missing from blocked, and this is exactly the watershed for treatment direction. Corrected means a coagulation factor is deficient, typically hemophilia A or B or von Willebrand disease; not corrected means an inhibitor, that is, an antibody, is present, typically acquired hemophilia A or lupus anticoagulant.

Hemophilia A splits into congenital and acquired forms, which look identical at first glance — a prolonged partial thromboplastin time plus low factor eight — yet their treatment directions could not be more different. The congenital form is an X-linked factor eight gene defect, affecting boys, with a bleeding pattern dominated by joint bleeding and deep intramuscular hematomas; the mixing test corrects, and treatment is simply replacing factor eight; severe disease is defined as factor eight under one percent, moderate one to five, mild five to forty. The acquired form is caused by autoantibodies against factor eight, affecting postpartum women and the elderly, with a bleeding pattern of large skin bruises and soft-tissue hematomas with little joint bleeding; the mixing test does not correct, and an inhibitor titer comes back positive. The ironclad treatment rule for the acquired form is that directly replacing high-dose factor eight is often of limited benefit because the antibody neutralizes it, so bypassing agents such as activated factor seven or activated prothrombin complex concentrate are used to control bleeding before the antibody has cleared, while immunosuppression with corticosteroids plus cyclophosphamide or rituximab gradually drives the antibody down. Keep this watershed of missing versus blocked in mind, and congenital and acquired will never again be confused.

Two axes localize every clot: see a prolonged PTT with a normal PT and think intrinsic pathway first; the mixing test corrects for missing, and fails to correct for blocked.

Von Willebrand disease is the most common inherited bleeding disorder. Deficiency or dysfunction of vWF disrupts hemostasis at two levels: primary hemostasis suffers from impaired platelet adhesion, because vWF is the essential bridge letting platelets stick to sites of endothelial injury; secondary hemostasis suffers because vWF is the carrier for factor eight, so a fall in vWF drags factor eight down with it. The classic tetrad is therefore menorrhagia or mucosal bleeding, plus a prolonged bleeding time, plus a prolonged partial thromboplastin time, plus a normal prothrombin time; the distinction from hemophilia is that VWD features mucosal bleeding and a prolonged bleeding time, while hemophilia is dominated by deep joint and muscle bleeding. Forgetting the prolonged partial thromboplastin time is a common way to lose points, because many people remember only that VWD is a disorder of primary hemostasis and forget that factor eight falls along with it.

Excessive anticoagulation without bleeding is another common trap. Warfarin excess without bleeding, for example an INR of five point four, is managed by holding warfarin or reducing the dose and observing, with low-dose oral vitamin K optionally added, but IV vitamin K is not immediately needed. Reflexively giving IV vitamin K just because the INR is high is wrong, because over-reversal without bleeding actually puts patients with mechanical valves at risk of thrombosis. Only in severe bleeding is four-factor prothrombin complex concentrate plus IV vitamin K used, with fresh frozen plasma as the second choice. Management of acute peripheral arterial thrombosis is primarily catheter-directed thrombolysis or surgical thrombectomy and bypass, not systemic thrombolysis, because systemic thrombolysis carries a high bleeding risk and arterial thrombi are rich in platelets and fibrin, making local treatment more effective.

Two axes localize every clot: see a prolonged PTT with a normal PT and think intrinsic pathway first; the mixing test corrects for missing, and fails to correct for blocked.

Pseudothrombocytopenia is likewise a gift question: inside an EDTA collection tube, platelets clump together because of EDTA-induced agglutination, and the analyzer counts each clump as a single cell, falsely reporting a low count, yet the patient has absolutely no clinical bleeding — the giveaway that it is spurious. Confirmation comes from redrawing into a tube free of EDTA, such as sodium citrate, or checking the smear for platelet clumps, rather than using a heparin tube, which introduces its own coagulation interference. Last is the paradox of the lupus anticoagulant: one of the antiphospholipid antibodies, it interferes with phospholipid-dependent clotting assays in vitro, so the partial thromboplastin time is prolonged and the mixing test fails to correct, yet in vivo it actually promotes thrombosis — the paradox baked right into its name, called an anticoagulant yet causing clots. See a prolonged partial thromboplastin time together with recurrent thrombosis or miscarriage, and think of it; never mistake it for something that causes bleeding. Hold this chapter's throughline — the two axes of prothrombin time and partial thromboplastin time, together with the mixing test's separation of missing from blocked — and every bleeding and coagulation question can be reasoned through in turn.

🌙 On-call challenge — take this chapter's patient in English (OET Station 5) →

6. Pediatric Solid Tumors, Purpura, and Transfusion: Three Clinical Scenarios

The key to pediatric tumor questions is age; the key to hematologic emergencies is whether the platelet count is normal or low; the key to general oncology is the first move in an emergency. Add the ABO logic of transfusion medicine on top, and this chapter clears out every "clinical scenario" question.

The Pediatric Cancer Map: Age Dictates the First Instinct

Tumor	Peak age	Key clues
ALL	2-5 years	Most common childhood leukemia (~75-80%); bone pain, fever, anemia, bruising
AML	Infancy, adolescence; Down syndrome at 1-3 years	Auer rods; AML predominates in Down syndrome children at this age
Neuroblastoma	<1 year (peak in infancy)	Most common extracranial solid tumor in children; adrenal/sympathetic-chain mass, crosses the midline, urinary VMA/HVA↑; MYCN amplification = poor prognosis
Wilms tumor	2-5 years	Renal mass does not cross the midline, hematuria
Retinoblastoma	<3 years	Leukocoria, RB1 gene
Hodgkin lymphoma	Adolescence to young adulthood	Painless cervical lymphadenopathy, Reed-Sternberg cells

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

🔬 Mechanism, unpacked

Why does age separate these tumors so cleanly? Break the causal chain into five steps: ① every pediatric tumor arises from cells at a specific stage of development; ② neuroblastoma arises from neural crest cells, an early cell type in neural development, so it clusters in infancy; ③ Wilms tumor arises from nephroblasts (residual metanephric blastema), and this cell population does not finish involuting until 2-5 years, so it peaks at 2-5 years; ④ retinoblastoma arises from retinoblasts, most common within 3 years; ⑤ ALL is a lymphoid precursor cell, Hodgkin lymphoma a differentiating B cell — the earlier the cell of origin, the earlier the tumor appears, and the later the differentiation stage, the older the age of onset. That is the secret behind age as a locator.

Fix two exam mnemonics for life: "an abdominal mass under one year of age" → think neuroblastoma first (crosses the midline, VMA/HVA elevated); "fever plus bone pain plus abnormal complete blood count at 2-5 years" → think ALL first.

Neuroblastoma carries two classic paraneoplastic clues as well: opsoclonus-myoclonus syndrome ("dancing eyes") and periorbital ecchymosis from orbital metastasis ("raccoon eyes"). The tumor-marker trap question loves to ask: neuroblastoma = urinary VMA/HVA, not AFP — AFP is the marker for hepatoblastoma and germ cell tumor (yolk sac type).

Differentiating Pediatric Purpura: The First Cut Is "Platelet Count"

Disease	Platelets	Mechanism	Hallmark features
HSP (Henoch-Schönlein purpura / IgA vasculitis)	Normal	IgA immune-complex small-vessel vasculitis (not consumptive)	Palpable purpura (lower extremities/buttocks) + abdominal pain + arthralgia + nephritis (IgA)
Immune thrombocytopenia (ITP)	↓↓	Autoantibody-mediated platelet destruction (often post-viral infection)	Isolated thrombocytopenia, other cell lines normal
Hemolytic uremic syndrome (HUS)	↓	Shiga toxin → endothelial injury, microangiopathy	Triad: hemolytic anemia + ↓platelets + acute kidney injury; often follows bloody diarrhea from enterohemorrhagic E. coli (EHEC)
Hemophagocytic lymphohistiocytosis (HLH)	↓	Macrophage hyperactivation, hemophagocytosis	Fever + hepatosplenomegaly + pancytopenia + ferritin↑↑, triglycerides↑, fibrinogen↓

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

HSP has a normal platelet count — its purpura comes from "inflamed vessel walls," not "insufficient platelets." This is the dividing line from the other three.

HLH is also easy to reverse in memory, so pin it down: thrombocytopenia (not thrombocytosis), fibrinogen falls (not rises), ferritin extremely high (>500, or >10,000 under some diagnostic criteria). Also watch for thrombotic thrombocytopenic purpura (TTP), which likewise presents with microangiopathic hemolysis and thrombocytopenia — its mechanism is ADAMTS13 deficiency, so oversized vWF multimers cannot be cleaved down, and platelets keep getting snagged into microthrombi; the pentad is fever, neurologic symptoms, renal injury, thrombocytopenia, and microangiopathic hemolysis.

Transfusion Principles in Severe β-Thalassemia

(This topic was covered in detail in Chapter 2; this chapter gives a quick review of the test points to close out the clinical picture.) The core of transfusion: keep Hb at a higher target (roughly above 9-10.5 g/dL) → suppress compensatory marrow expansion → prevent extramedullary hematopoiesis (hepatosplenomegaly, skeletal deformity, hair-on-end skull appearance). The cost is iron overload → iron chelation; cure requires HSCT.

General Oncology: The Carcinogenesis Chain, Markers, and Emergencies

The essence of cancer is genomic instability driving uncontrolled cell proliferation. One sentence strings together most of the test points: carcinogen/virus/inherited mutation → drives oncogene activation or tumor-suppressor inactivation → loss of cell-cycle control, evasion of apoptosis and immune surveillance → invasion and metastasis.

Mechanism category	Representative	One-line summary
Oncogene activation	HER2/neu (breast cancer), RAS, MYC	Stuck "gas pedal," drives proliferation
Tumor-suppressor inactivation	TP53, RB, BRCA1/2	"Brake failure," loss of repair and apoptosis
Viral carcinogenesis	HPV (head and neck, cervix), HBV/HCV (liver), EBV (nasopharynx)	Viral proteins inactivate tumor suppressors

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

Several high-yield details to remember: HPV-related head and neck cancer carries a better prognosis than HPV-negative disease — HPV(+) oropharyngeal cancer occurs more often in younger, non-smoking patients, responds well to chemoradiation, and has higher survival; HPV-negative disease (linked to smoking/alcohol) carries a worse prognosis. BRCA1 confers a higher ovarian cancer risk than BRCA2 (lifetime ovarian cancer risk roughly 40-60% for BRCA1 versus roughly 10-20% for BRCA2); breast cancer risk is elevated with both. Progestin is a "protective factor" for endometrial cancer, not a risk factor — the core mechanism of endometrial cancer is unopposed estrogen stimulation, and progestin counteracts it; the true risk factors are obesity, nulliparity, polycystic ovaries, tamoxifen, and late menopause.

Tumor markers are mostly used to track treatment response and recurrence; a few can aid diagnosis, and almost none should be used alone for screening:

Marker	Tumor	Key point
PSA	Prostate cancer	Prostate cancer does not use LDH
AFP	Hepatocellular carcinoma, germ cell tumor (yolk sac)
CEA	Colorectal cancer (tracks recurrence)	Not specific
CA-125	Ovarian cancer	Mainly for monitoring
CA 19-9	Pancreatic cancer
β-hCG	Choriocarcinoma, germ cell tumor
LDH	Lymphoma, germ cell tumor, marker of tumor burden	Not a prostate cancer marker

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

Treatment-direction questions by organ system: stage IV renal cell carcinoma (RCC) does not respond to conventional chemotherapy; effective options are immunotherapy (checkpoint inhibitors), anti-angiogenic therapy (VEGF TKIs such as sunitinib), and mTOR inhibitors; RCC is also relatively radioresistant. Early-stage laryngeal cancer can be treated with radiotherapy to preserve laryngeal function (organ preservation), avoiding total laryngectomy. For HER2-overexpressing breast cancer, adding adjuvant trastuzumab (anti-HER2) after surgery improves overall survival.

The "first move" in oncologic emergencies is a guaranteed-point exam topic:

Emergency	Typical clues	First-line management
Metastatic spinal cord compression (MSCC)	Back pain + lower-extremity weakness/sensory change/incontinence	Immediate high-dose dexamethasone + emergent MRI; radiotherapy or surgical decompression
Superior vena cava syndrome (SVC syndrome)	Facial/upper-extremity swelling, jugular venous distension, dyspnea (usually lung cancer/lymphoma)	Elevate the head of the bed, confirm with imaging, treat the underlying tumor (radiotherapy/chemotherapy)
Hypercalcemia	Polyuria, constipation, altered mental status, bone pain	Aggressive normal saline hydration (first step, fastest) + bisphosphonate (durable calcium-lowering effect but takes 2-4 days to act); calcitonin acts fast and can bridge; thiazides contraindicated
Tumor lysis syndrome (TLS)	Hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia (post-chemotherapy)	Aggressive hydration + uric-acid lowering; rasburicase for high-risk/established disease, allopurinol for prophylaxis (rasburicase contraindicated in G6PD deficiency); monitor for hyperkalemic arrhythmia

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

Transfusion Medicine: ABO Logic and Acute Hemolytic Reactions

🔬 Mechanism, unpacked

The ABO system runs on one key principle; break the causal chain into four steps: ① plasma naturally contains IgM antibodies "against the antigen it does not itself carry"; ② so type A plasma has anti-B, type B plasma has anti-A, type O plasma has both anti-A and anti-B, and type AB plasma has neither antibody; ③ apply this principle to "red cell transfusion looks at antigen, plasma transfusion looks at antibody," and the direction becomes clear: for red cell transfusion, type O is the universal donor (no A/B antigen to be attacked), while for plasma transfusion, type AB is the universal donor (no anti-A, no anti-B); ④ the two directions run exactly opposite, so the "universal donor" differs depending on which component is transfused — the universal red cell donor is type O (strictly O-negative), while the universal plasma donor is type AB.

Blood type	Red cell antigen	Plasma antibody
A	A	Anti-B
B	B	Anti-A
O	None	Anti-A + anti-B
AB	A, B	None

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

Giving type A red cells to a type O patient → the type O plasma's anti-A immediately attacks the transfused A red cells → acute intravascular hemolysis. This must never be given, even in an emergency — the real emergency solution is to issue type O blood, not to force through an incompatible unit; there is no such thing as "relaxing major ABO incompatibility because it's an emergency."

Rh matters just as much: the true universal red cell donor is O Rh-negative (O−) — if an Rh− recipient (especially a woman of childbearing age) receives Rh+ blood, she can become sensitized, triggering future hemolytic disease of the fetus and newborn (HDFN).

Acute hemolytic transfusion reaction (AHTR): the mechanism is major ABO incompatibility → recipient antibody + complement → intravascular hemolysis; most often caused by human error in crossmatching or mislabeling blood. Presentation: fever, chills, back pain, hemoglobinuria, hypotension, and DIC appearing during the transfusion itself. First step in management: stop the transfusion immediately, maintain fluids and diuresis to protect the kidneys, and notify the blood bank to recheck.

Three transfusion reactions must be distinguished clearly:

Reaction	Mechanism/timing	Key distinguishing feature	Management
TRALI (transfusion-related acute lung injury)	Donor anti-HLA/anti-granulocyte antibodies → non-cardiogenic pulmonary edema; within 6 hours of transfusion	Fever, hypotension, hypoxia, bilateral pulmonary infiltrates without volume overload (BNP normal, PAWP normal)	Supportive care/respiratory support, not diuresis
TACO (transfusion-associated circulatory overload)	Transfusion volume/rate too high → cardiogenic pulmonary edema; common in the elderly and those with poor cardiac/renal function	Hypertension, jugular venous distension, elevated BNP; responds to diuresis	Slow/stop the transfusion, diuretics, oxygen
Delayed hemolytic transfusion reaction (DHTR)	Re-exposure to a minor antibody from prior sensitization (e.g., anti-Kidd/Rh), causing extravascular hemolysis days later	Hb fails to rise or falls after transfusion, indirect bilirubin↑, Coombs turns positive	Usually self-limited; monitor and support

Swipe or scroll sideways to compare every column; keyboard: focus the table and use arrow keys.

TRALI vs. TACO: both present with acute respiratory distress and pulmonary infiltrates after transfusion, but TRALI has no volume overload (diuresis ineffective, BNP normal), while TACO is volume overload (diuresis effective, BNP↑).

Finally, HSCT sources: qualified sources are all tissues rich in CD34+ hematopoietic stem cells — bone marrow (direct aspiration), peripheral blood stem cells (PBSC) (mobilized into the blood with G-CSF first, then collected — now the most commonly used), and umbilical cord blood (fewer stem cells but lower immunogenicity, allowing more permissive HLA matching). "Adult splenic cells" do not qualify — the spleen is a lymphoid/reticuloendothelial organ, not a storage site for hematopoietic stem cells (adult hematopoiesis occurs mainly in the bone marrow); this is a standard exam trap.

⭐ Board-exam essentials

Pediatrics, Emergencies, and Transfusion — Must-Know Checklist

Pediatric cancer map: ALL at 2-5 years (most common childhood leukemia); neuroblastoma <1 year (most common extracranial solid tumor, crosses the midline, VMA/HVA↑, MYCN amplification = poor prognosis); Wilms at 2-5 years, does not cross the midline; retinoblastoma <3 years, leukocoria, RB1. Down syndrome leukemia at 1-3 years is predominantly AML.
Neuroblastoma marker = urinary VMA/HVA (not AFP); paraneoplastic clues are dancing eyes and raccoon eyes.
Cut pediatric purpura by platelet count: HSP has normal platelets (IgA vasculitis, palpable purpura); ITP/HUS/HLH all have low platelets; HLH = ferritin↑↑, TG↑, fibrinogen↓.
Tumor markers: prostate = PSA (not LDH); HPV(+) head and neck cancer has a better prognosis; BRCA1 carries a higher ovarian cancer risk than BRCA2; progestin is a protective factor for endometrial cancer.
Treatment direction: stage IV RCC does not respond to conventional chemotherapy (immunotherapy/VEGF TKI/mTOR); early laryngeal cancer can preserve the larynx with radiotherapy; HER2(+) breast cancer improves survival with postoperative trastuzumab.
First move in emergencies: spinal cord compression = dexamethasone + MRI; SVC syndrome = treat the underlying tumor; hypercalcemia = normal saline hydration (thiazides contraindicated); TLS = hydration + uric-acid lowering (rasburicase, contraindicated in G6PD deficiency).
Transfusion ABO: red cells: O is the universal donor (strictly O−); plasma: AB is the universal donor (opposite directions); giving A red cells to an O patient = acute intravascular hemolysis, contraindicated (no relaxing this even in an emergency).
AHTR = major ABO incompatibility → intravascular hemolysis; first step = stop the transfusion immediately.
TRALI: no volume overload/diuresis ineffective; TACO: volume overload/BNP↑, diuresis effective.
Qualified HSCT sources = bone marrow, PBSC, umbilical cord blood; disqualified = adult splenic cells.
Traps: writing HSP as having low platelets (actually normal); answering the neuroblastoma marker as AFP (actually VMA/HVA); writing that prostate cancer is tracked with LDH (actually PSA); writing progestin as a risk factor for endometrial cancer (actually protective); giving type A red cells to a type O patient in an emergency (causes intravascular hemolysis); treating adult splenic cells as a qualified HSCT source.

♪ Sing-along text — English rendering of the Mandarin song lyrics

🎵 Chapter song　血液腫瘤・小兒實體腫瘤、紫斑與輸血Spotify Apple Music

Alternate take (Version B): Spotify · Apple Music

Sung in Mandarin by Otter Whistle · album 《醫學國考・血液腫瘤》 · the text below is an English rendering of the lyrics

The key to pediatric tumor questions is age; the key to hematologic emergencies is whether the platelet count is normal or low; the key to general oncology is the first move in an emergency. Hold these three coordinates and the clinical-scenario questions sort themselves out. Why does age separate them so cleanly? Because every tumor arises from a specific developmental cell type. Neuroblastoma arises from neural crest cells, an early cell type in neural development, so it clusters in infancy. Wilms tumor arises from nephroblasts, a residue of early kidney development, so it peaks between two and five years. Retinoblastoma arises from retinoblasts, most common within three years. Acute lymphoblastic leukemia is a lymphoid precursor cell. Hodgkin lymphoma is a differentiating B cell — the earlier the cell of origin, the earlier the tumor appears.

Under one year, crossing the midline, is neuroblastoma; two to five years, not crossing the midline, is Wilms tumor; remember the marker as VMA, not alpha-fetoprotein.

Acute lymphoblastic leukemia is the most common childhood leukemia, accounting for seventy-five to eighty percent, peaking at two to five years, typically presenting with fever plus bone pain plus abnormal complete blood counts plus bruising and bleeding. Acute myeloid leukemia occurs in both infancy and adolescence; in children with Down syndrome, the most common leukemia at one to three years is predominantly acute myeloid leukemia, so do not assume childhood leukemia always means acute lymphoblastic leukemia. Neuroblastoma is the most common extracranial solid tumor in children, arising from the adrenal gland or sympathetic chain, presenting with an abdominal mass crossing the midline and elevated urinary VMA and homovanillic acid; MYCN amplification means a poor prognosis. Paraneoplastic clues include dancing eyes, that is, opsoclonus-myoclonus syndrome, along with periorbital ecchymosis from orbital metastasis, resembling raccoon eyes. Wilms tumor, also called nephroblastoma, occurs at two to five years, with a renal mass that does not cross the midline and hematuria. Retinoblastoma occurs within three years, with leukocoria plus the RB1 gene. The marker trap most loves to ask: the neuroblastoma marker is VMA and homovanillic acid, not alpha-fetoprotein — alpha-fetoprotein belongs to hepatoblastoma or the yolk sac type of germ cell tumor.

The first cut in pediatric purpura is whether the platelet count is normal or low. Henoch-Schönlein purpura, that is, immunoglobulin A vasculitis, has a normal platelet count, because it is an immunoglobulin A immune-complex small-vessel vasculitis rather than a consumptive process, so the purpura comes from inflammation of the vessel wall rather than a shortage of platelets; its hallmark is palpable purpura over the lower extremities and buttocks plus abdominal pain plus joint pain plus immunoglobulin A nephritis. Immune thrombocytopenia is autoantibody destruction of platelets that often follows a viral infection; the causal chain is that the virus induces an anti-platelet immunoglobulin G antibody, the antibody binds surface glycoprotein on the platelet, and it is cleared by splenic macrophages, so the platelet count alone drops extremely low while the other cell lines stay normal. Hemolytic uremic syndrome is Shiga toxin causing endothelial injury and microangiopathy; the triad is hemolytic anemia plus falling platelets plus acute kidney injury, often following bloody diarrhea from enterohemorrhagic E. coli. Hemophagocytic lymphohistiocytosis is also easy to get backward in memory, so pin it down: platelets are low, not elevated; fibrinogen falls, not rises; while ferritin runs extremely high, triglycerides rise, and there is fever plus hepatosplenomegaly plus pancytopenia. The dividing line between Henoch-Schönlein purpura and immune thrombocytopenia is exactly the platelet count — normal in the former, extremely low in the latter.

Under one year, crossing the midline, is neuroblastoma; two to five years, not crossing the midline, is Wilms tumor; remember the marker as VMA, not alpha-fetoprotein.

General oncology holds onto three main lines. The carcinogenesis chain is genomic instability plus oncogene activation or tumor-suppressor inactivation, so HER2, RAS, and MYC belong to the gas-pedal category, while p53, RB, BRCA1, and BRCA2 belong to the brake category; among viral carcinogens, HPV dominates head and neck and cervical cancer, hepatitis B and C viruses dominate liver cancer, and Epstein-Barr virus dominates nasopharyngeal cancer. A few directions worth remembering: HPV-positive head and neck cancer has a better prognosis than HPV-negative disease, because the former occurs more often in younger, non-smoking patients who respond well to chemoradiation; BRCA1 carries a markedly higher ovarian cancer risk than BRCA2, a lifetime risk of roughly forty to sixty percent versus roughly ten to twenty percent; progestin is not a risk factor but a protective factor, because the core mechanism of endometrial cancer is unopposed estrogen stimulation, and progestin counteracts it — the true risks are obesity, nulliparity, polycystic ovaries, tamoxifen, and late menopause.

Tumor markers are mostly used for monitoring and rarely stand alone for screening or diagnosis — diagnosis rests on pathology. The pairings must be memorized cold: prostate cancer uses PSA, not lactate dehydrogenase, and that is a high-frequency trap; alpha-fetoprotein points to hepatocellular carcinoma and the yolk sac type of germ cell tumor; carcinoembryonic antigen is a non-specific marker used to track recurrence in colorectal cancer; CA-125 tracks ovarian cancer; CA 19-9 is for pancreatic cancer; human chorionic gonadotropin marks choriocarcinoma and germ cell tumors; lactate dehydrogenase is an indicator of lymphoma, germ cell tumor, and overall tumor burden, not a prostate cancer marker. On treatment-direction questions: stage IV renal cell carcinoma does not respond to conventional chemotherapy, and the effective options are immunotherapy, anti-angiogenic tyrosine kinase inhibitors such as sunitinib, and mTOR inhibitors; early laryngeal cancer can be treated with radiotherapy to preserve laryngeal function and avoid total laryngectomy; breast cancer with HER2 overexpression adds postoperative trastuzumab to improve overall survival.

Under one year, crossing the midline, is neuroblastoma; two to five years, not crossing the midline, is Wilms tumor; remember the marker as VMA, not alpha-fetoprotein.

The first move in oncologic emergencies is a guaranteed-point question. For spinal cord compression, look for back pain plus lower-extremity weakness or loss of bowel and bladder control, give immediate high-dose dexamethasone plus emergent magnetic resonance imaging, followed by radiotherapy or surgical decompression. For superior vena cava syndrome, look for facial and upper-extremity swelling, jugular venous distension, and dyspnea, usually from lung cancer or lymphoma, and manage with head-of-bed elevation plus imaging plus treatment directed at the tumor. For hypercalcemia, look for polyuria, constipation, altered mental status, and bone pain; the first step is always aggressive normal saline hydration, which is the fastest and safest; bisphosphonates treat the underlying cause but take two to four days to work; calcitonin acts quickly and can bridge the gap; and thiazides are contraindicated because they themselves retain calcium. Tumor lysis syndrome appears early in chemotherapy as hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia; manage with aggressive hydration plus uric-acid lowering — rasburicase for high-risk or already-established disease, though it is contraindicated in G6PD deficiency, with allopurinol available for prophylaxis.

Last comes the antigen-antibody logic of blood typing in transfusion medicine. The key principle is that plasma naturally contains antibodies against whichever antigen it does not itself carry, so type A has anti-B, type B has anti-A, type O has both anti-A and anti-B, and type AB has neither antibody. Apply this antigen-antibody logic so that red cell transfusion looks at antigen and plasma transfusion looks at antibody, and the direction becomes clear: for red cell transfusion, type O is the universal donor, strictly speaking O-negative, while for plasma transfusion, type AB is the universal donor — the two directions run exactly opposite. So giving type A red cells to a type O patient lets the anti-A in the type O plasma tear straight through them into acute intravascular hemolysis; this must never be given even in an emergency, since the real emergency solution is to issue type O red cells, not to force through an incompatible unit. The mechanism of an acute hemolytic transfusion reaction is major ABO incompatibility plus complement, causing intravascular hemolysis; the first step in management is to stop the transfusion immediately, maintain fluids and diuresis to protect the kidneys, and notify the blood bank to recheck. Transfusion-related lung injury and circulatory overload must be told apart: both present as acute respiratory distress plus pulmonary infiltrates after transfusion, but transfusion-related acute lung injury is non-cardiogenic pulmonary edema caused by anti-human-leukocyte-antigen or anti-granulocyte antibodies, with no volume overload, diuresis ineffective, and brain natriuretic peptide normal, requiring respiratory support; transfusion-associated circulatory overload is cardiogenic pulmonary edema from transfusing too much too fast, with volume overload, diuresis effective, and brain natriuretic peptide elevated. Finally, the qualified sources for hematopoietic stem cell transplantation are bone marrow, peripheral blood stem cells, and umbilical cord blood, all rich in CD34-positive hematopoietic stem cells, while adult splenic cells are not a source, because the spleen is a lymphoid and reticuloendothelial organ and adult hematopoiesis occurs mainly in the bone marrow — this is a standard trap. The whole book closes into one sentence: look at the cell, look at the age, look at the platelet count, and the question answers itself.

🌙 On-call challenge — take this chapter's patient in English (OET Station 6) →